<?xml version="1.0" encoding="utf-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:og="http://ogp.me/ns#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:schema="http://schema.org/" xmlns:sioc="http://rdfs.org/sioc/ns#" xmlns:sioct="http://rdfs.org/sioc/types#" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" version="2.0" xml:base="https://rtaylor193.github.io/insureintell-1col/">
  <channel>
    <title>alcohol use</title>
    <link>https://rtaylor193.github.io/insureintell-1col/</link>
    <description/>
    <language>en</language>
    
    <item>
  <title>Presentations from the 2018 WAHLU Spring Seminar</title>
  <link>https://rtaylor193.github.io/insureintell-1col/node/26018</link>
  <description>&lt;span&gt;Presentations from the 2018 WAHLU Spring Seminar&lt;/span&gt;
&lt;span&gt;&lt;a title="View user profile." href="https://rtaylor193.github.io/insureintell-1col/user/582" lang="" about="https://rtaylor193.github.io/insureintell-1col/user/582" typeof="schema:Person" property="schema:name" datatype="" xml:lang=""&gt;matt&lt;/a&gt;&lt;/span&gt;
&lt;span&gt;Fri, 05/18/2018&lt;/span&gt;

            &lt;div&gt;&lt;p&gt;Slides from the 2018 Wisconsin Association of Health and Life Underwriters have been posted at the WAHLU website.&lt;/p&gt;

&lt;p&gt;Presentations include:&lt;/p&gt;&lt;/div&gt;
      
  &lt;div&gt;
    &lt;div&gt;Link&lt;/div&gt;
              &lt;div&gt;&lt;a href="http://wahlu.org/presentations/"&gt;http://wahlu.org/presentations/&lt;/a&gt;&lt;/div&gt;
          &lt;/div&gt;

  &lt;div&gt;
    &lt;div&gt;Tags&lt;/div&gt;
          &lt;div&gt;
              &lt;div&gt;&lt;a href="https://rtaylor193.github.io/insureintell-1col/taxonomy/term/63" hreflang="en"&gt;drugs&lt;/a&gt;&lt;/div&gt;
          &lt;div&gt;&lt;a href="https://rtaylor193.github.io/insureintell-1col/taxonomy/term/37" hreflang="en"&gt;alcohol use&lt;/a&gt;&lt;/div&gt;
          &lt;div&gt;&lt;a href="https://rtaylor193.github.io/insureintell-1col/taxonomy/term/277" hreflang="en"&gt;asthma&lt;/a&gt;&lt;/div&gt;
          &lt;div&gt;&lt;a href="https://rtaylor193.github.io/insureintell-1col/taxonomy/term/496" hreflang="en"&gt;COPD&lt;/a&gt;&lt;/div&gt;
          &lt;div&gt;&lt;a href="https://rtaylor193.github.io/insureintell-1col/taxonomy/term/198" hreflang="en"&gt;underwriting rx&lt;/a&gt;&lt;/div&gt;
              &lt;/div&gt;
      &lt;/div&gt;
</description>
  <pubDate>Fri, 18 May 2018 01:05:10 +0000</pubDate>
    <dc:creator>matt</dc:creator>
    <guid isPermaLink="false">26018 at https://rtaylor193.github.io/insureintell-1col</guid>
    </item>
<item>
  <title>Tis the Season to Be (Not Too) Merry - Safe Levels of Alcohol</title>
  <link>https://rtaylor193.github.io/insureintell-1col/node/25218</link>
  <description>&lt;span&gt;Tis the Season to Be (Not Too) Merry - Safe Levels of Alcohol&lt;/span&gt;
&lt;span&gt;&lt;a title="View user profile." href="https://rtaylor193.github.io/insureintell-1col/user/582" lang="" about="https://rtaylor193.github.io/insureintell-1col/user/582" typeof="schema:Person" property="schema:name" datatype="" xml:lang=""&gt;matt&lt;/a&gt;&lt;/span&gt;
&lt;span&gt;Thu, 12/15/2016&lt;/span&gt;

            &lt;div&gt;&lt;p&gt;We often link alcohol abuse with liver damage but it’s also associated with cancers and diseases of the cardiovascular, neurological and gastrointestinal systems.&lt;/p&gt;&lt;/div&gt;
      
  &lt;div&gt;
    &lt;div&gt;Tags&lt;/div&gt;
          &lt;div&gt;
              &lt;div&gt;&lt;a href="https://rtaylor193.github.io/insureintell-1col/taxonomy/term/84" hreflang="en"&gt;alcohol abuse&lt;/a&gt;&lt;/div&gt;
          &lt;div&gt;&lt;a href="https://rtaylor193.github.io/insureintell-1col/taxonomy/term/85" hreflang="en"&gt;alcohol markers&lt;/a&gt;&lt;/div&gt;
          &lt;div&gt;&lt;a href="https://rtaylor193.github.io/insureintell-1col/taxonomy/term/37" hreflang="en"&gt;alcohol use&lt;/a&gt;&lt;/div&gt;
              &lt;/div&gt;
      &lt;/div&gt;
</description>
  <pubDate>Thu, 15 Dec 2016 21:49:03 +0000</pubDate>
    <dc:creator>matt</dc:creator>
    <guid isPermaLink="false">25218 at https://rtaylor193.github.io/insureintell-1col</guid>
    </item>
<item>
  <title>Drunk Driving and Insurability</title>
  <link>https://rtaylor193.github.io/insureintell-1col/node/25712</link>
  <description>  &lt;div data-history-node-id="25712" class="layout layout--onecol"&gt;
    &lt;div class="layout__region layout__region--content"&gt;
      
  &lt;div&gt;
    &lt;div&gt;Body&lt;/div&gt;
              &lt;div property="schema:text"&gt;&lt;p&gt;&lt;strong&gt;Hank George, FALU, CLU, FLMI&lt;/strong&gt;&lt;/p&gt;

&lt;p style="padding-top: 2em"&gt;&lt;em&gt;"The World Health Organization has estimated that, by 2020, motor vehicle accidents (MVAs) will be second only to ischemic heart disease as a cause of years of life lost and third as a cause of disability after ischemic heart disease and depression."&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Richard A. Mayo, BM, BCh&lt;br /&gt;
Oxford University&lt;br /&gt;
Psychiatric Clinics of North America&lt;br /&gt;
25(2002):27&lt;/p&gt;

&lt;p&gt;&lt;em&gt;"Although alcohol-related fatal crashes were substantially reduced between 1982 and 1995, there has been little change over the last 10 years."&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;James D. Fell, et al&lt;br /&gt;
Pacific Institute for Research and Evaluation&lt;br /&gt;
Annals of Advances in Automotive Medicine&lt;br /&gt;
53(2009):63&lt;/p&gt;

&lt;p&gt;Traffic crashes are the leading cause of death at ages 2 to 33 in the USA and many other western countries. [Hingson]&lt;/p&gt;

&lt;p style="padding-top: 2em"&gt;&lt;strong&gt;How common is driving under the influence?&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;In a 2011 survey, 1.8% of American adults admitted to driving drunk at least once in the prior year. This equates to roughly 4 million people. [MMWR, 2011]&lt;/li&gt;
	&lt;li&gt;Epidemiologic calculations suggest that there were 112 million drunken driving events in 2010, which is down 31% from the prior year's estimate. [MMWR, 2011]&lt;/li&gt;
	&lt;li&gt;In the USA, 1.4 million motorists are arrested (and in most cases, convicted) for driving while intoxicated (DWI). [Furr-Holden]&lt;/li&gt;
	&lt;li&gt;The odds of a person with a BAC (blood alcohol content) of 0.10 being arrested for DWI on a given driving episode is estimated at no more than 1 in 200. [Beitel]&lt;/li&gt;
	&lt;li&gt;Roughly 1/3rd of all US motor vehicle crash fatalities involved drivers with a blood alcohol content of at least 0.08, consistent with unequivocal intoxication. [MMWR, 2011]&lt;/li&gt;
	&lt;li&gt;In a new study of 16,942 fatal crashes, 40% of fatally injured drivers had a BAC of 0.08 or higher. [Romano]&lt;/li&gt;
	&lt;li&gt;In another new study, this one with 20,150 fatal car accidents, 40% of drivers killed in these accidents were intoxicated. [Brady]&lt;/li&gt;
	&lt;li&gt;In Canada, 28% of fatally injured drivers at ages 26-35 had BAC concentrations at or above the same threshold. [Maskalyk]&lt;/li&gt;
	&lt;li&gt;20% of serious auto accidents in urban China are attributed to alcohol excess and this number is thought to be an understatement due to imperfect record keeping. [Li, Rao]&lt;/li&gt;
	&lt;li&gt;In Ireland, 30% of drivers in fatal crashes were intoxicated. [Bedford]&lt;/li&gt;
	&lt;li&gt;In Australia, it was 29% [Drummer]&lt;/li&gt;
	&lt;li&gt;Only 14% of drunken drivers in American fatal crashes have an existing diagnosis of alcohol dependency; therefore, the vast majority will not have a clinical history of an alcohol use disorder. [Furr-Holden]&lt;/li&gt;
&lt;/ul&gt;

&lt;p style="padding-top: 2em"&gt;&lt;strong&gt;What about intoxicated use of a motorcycle?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;"…drinking and riding a motorcycle is a stubborn problem in which total alcohol-related crashes are increasing…the number of fatal motorcycle crashes began to climb in 1998 and have risen each year since."&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Fell&lt;br /&gt;
Op.Cit.&lt;/p&gt;

&lt;p&gt;The incidence of positive BAC tests is 24% greater in motorcycle vs. car fatalities. [Fell]&lt;/p&gt;

&lt;p&gt;In a 2004 investigation [MMWR, 2004]:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;48% of fatally injured motorcyclists were intoxicated.&lt;/li&gt;
	&lt;li&gt;Peak death rate in this setting shifted from ages 20-24 to ages 40-44.&lt;/li&gt;
	&lt;li&gt;Over age 34, the % of drunken motorcyclists was higher than the % of drunk automobile drivers.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;In a recent investigation, 49% of moped operators injured in accidents had a positive blood alcohol level, 45% had a prior DWI and 72% of those were repeat offenders.&lt;/p&gt;

&lt;p&gt;In addition, 38% had a revoked license at the time of injury and half of these individuals had multiple revocations. [Brintzenhoff]&lt;/p&gt;

&lt;p style="padding-top: 2em"&gt;&lt;strong&gt;What are the &lt;span style="color:#FC0;"&gt;YELLOW&lt;/span&gt; and &lt;span style="color:#900;"&gt;RED FLAGS&lt;/span&gt; for an increased risk of being an intoxicated driver?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Overall, the risk is higher in males and in persons smoking &gt; 1 pack of cigarettes per day.&lt;/p&gt;

&lt;p&gt;Major risk factors include:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;History of substance abuse, including prescription drugs&lt;/li&gt;
	&lt;li&gt;Binge drinking is the #1 predictor; defined as taking 5 or more drinks at one sitting&lt;/li&gt;
	&lt;li&gt;Habitually not wearing seat belt&lt;/li&gt;
	&lt;li&gt;Single vehicle accidents and/or striking fixed vs. moving objects&lt;/li&gt;
	&lt;li&gt;Car crashes occurring between midnight and sunrise&lt;/li&gt;
	&lt;li&gt;Prior convictions for reckless driving, driving too fast for conditions, weaving in and out of traffic, and failure to keep in the proper lane&lt;/li&gt;
	&lt;li&gt;Any criminal history&lt;/li&gt;
	&lt;li&gt;Antisocial personality disorder&lt;/li&gt;
	&lt;li&gt;Borderline personality disorder&lt;/li&gt;
	&lt;li&gt;Multiple current psychiatric disorders, especially mood-related (depression, bipolar disorder, etc.)&lt;/li&gt;
	&lt;li&gt;Frequent/sustained use of benzodiazepines for sleep-related purposes&lt;/li&gt;
	&lt;li&gt;Prior driver's license suspension/revocation&lt;/li&gt;
	&lt;li&gt;"Open container" violations (driving with an open bottle of an alcoholic beverage)&lt;/li&gt;
	&lt;li&gt;Frequently engaging in risk-taking behaviors such as extensive gambling, poor health practices, etc.&lt;/li&gt;
	&lt;li&gt;Delay in reinstatement of suspended/revoked driver's license&lt;/li&gt;
	&lt;li&gt;Elevated MCV on a complete blood count&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;[Birdsall, Blencowe, Fell, Freeman, Gjerde, Hingson, Pavanello, Romano, Sansone, Schermer, Voss, Wang]&lt;/p&gt;

&lt;p style="padding-top: 2em"&gt;&lt;strong&gt;Do many DWI/DUI convicts meet the criteria for an alcohol use disorder?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes, consistently in study after study:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Miller (1986): 73%&lt;/li&gt;
	&lt;li&gt;Parks (1996): 68%&lt;/li&gt;
	&lt;li&gt;Brinkmann (2002): 48%&lt;/li&gt;
	&lt;li&gt;Furr-Holden (2011): 50%&lt;/li&gt;
&lt;/ul&gt;

&lt;p style="padding-top: 2em"&gt;&lt;strong&gt;Is it likely that the % of DWI/DUI convicts diagnosed with an alcohol-related disorder will increase in the future?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes, because the criteria for this diagnosis have been liberalized substantially in the new edition of the American Psychiatric Association's Diagnostic and Statistical Manual (DSM-5).&lt;/p&gt;

&lt;p&gt;DSM-5 sets the criteria for psychiatric diagnoses in the United States and is widely used in other countries as well.&lt;/p&gt;

&lt;p&gt;This said, there has been great controversy over many of the changes embraced in this latest DSM edition and its overall impact remains clouded at this writing.&lt;/p&gt;

&lt;p style="padding-top: 2em"&gt;&lt;strong&gt;Which US States have the highest % of drivers involved in fatal crashes with a blood alcohol of 0.08 or higher?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In this order [Fell]:&lt;/p&gt;

&lt;ol&gt;
	&lt;li&gt;North Dakota&lt;/li&gt;
	&lt;li&gt;South Carolina&lt;/li&gt;
	&lt;li&gt;Montana&lt;/li&gt;
	&lt;li&gt;Wisconsin&lt;/li&gt;
	&lt;li&gt;Rhode Island&lt;/li&gt;
&lt;/ol&gt;

&lt;p style="padding-top: 2em"&gt;&lt;strong&gt;What do we know about DWI/DUI recidivism?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Recidivism refers to incurring 2nd and subsequent DWI/DUI convictions.&lt;/p&gt;

&lt;p&gt;&lt;em&gt;"For most individuals, being convicted of a DWI is a life-changing experience most do not want to repeat.&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;Conversely, individuals with at least two DWI's are at substantial risk of continued episodes of impaired driving either due to substance abuse problems or a denial that he engages in an activity that is harmful to himself or others."&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Danny Perkins, JD, FALU&lt;br /&gt;
Self-employed Underwriter/Attorney&lt;br /&gt;
On the Risk&lt;br /&gt;
28(2012):38&lt;/p&gt;

&lt;p&gt;&lt;em&gt;"Repeat offenders represent a group that is distinct not only from the general population but also…from the majority of first-time DUI offenders."&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Howard J. Shaffer, et al&lt;br /&gt;
Harvard University&lt;br /&gt;
Journal of Consulting and Clinical Psychology&lt;br /&gt;
75(2007):795&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;The recidivism rate after a first conviction is roughly 10% [Chaudhary]&lt;/li&gt;
	&lt;li&gt;The risk of a 2nd conviction is 10-fold greater than a first conviction; given 2 convictions, the odds of a third are 14-fold higher vs. having just one, and the likelihood continues to rise with additional convictions. [Rauch]&lt;/li&gt;
	&lt;li&gt;The average interval from 1st to 2nd DWI/DUI is 6 years, which raises questions about the value of temporary flat extra premiums in this setting…more on this later. [Cavaiola]&lt;/li&gt;
	&lt;li&gt;The risk of alcohol dependence (alcoholism) is higher in those with more than one DWI conviction whereas the odds of alcohol abuse only (without addiction) actually declines in persons with multiple convictions. [Couture, Shaffer]&lt;/li&gt;
	&lt;li&gt;Recidivists have a high prevalence of other criminality. [Hubicka]&lt;/li&gt;
	&lt;li&gt;Elevations of both GGT and CDT in first-time offenders are associated with a higher risk of recidivism. [Portman]&lt;/li&gt;
	&lt;li&gt;Repeat offenders have a 50% probability of comorbid drug use disorders, over 30% have major depression and at least 15% will be diagnosed with posttraumatic stress disorder. [Albanese, Lapham, Peller]&lt;/li&gt;
	&lt;li&gt;Conduct disorder in childhood and a history of problem gambling at any time are associated with a greater risk of a 2nd DWI/DUI. [LaPlante, Shaffer]&lt;/li&gt;
	&lt;li&gt;Prior traumatic brain injury is significantly more common in recidivists. [Ouimet]&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;And most comorbid psychiatric diagnoses in DWI/DUI offenders go unrecognized clinically! [McMillan]&lt;/p&gt;

&lt;p style="padding-top: 2em"&gt;&lt;strong&gt;Is there any clue to identifying the "hard core" drunken driver?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes – a blood alcohol of 0.15 mg/dL at any time. [Baker, Fell and Tippetts]&lt;/p&gt;

&lt;p&gt;These are clearly &lt;span style="color:#900;font-weight:bold;"&gt;RED FLAG&lt;/span&gt; cases.&lt;/p&gt;

&lt;p style="padding-top: 2em"&gt;&lt;strong&gt;Is there significant excess mortality in DWI/DUI?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes.&lt;/p&gt;

&lt;p&gt;In a Scandinavian study, mortality was 3.8 times expected after full adjustment for risk factors. [Karlsson]&lt;/p&gt;

&lt;p&gt;Mann found that mortality in DWI recidivists was 2.5-fold higher at ages 15-34, 2-fold greater at ages 35-54 and 1.3 times expected at older ages.&lt;/p&gt;

&lt;p&gt;For additional mortality information, see the superb &lt;a href="http://www.rgare.com/media-center/Documents/Motor%20Vehicle%20Records%20and%20All-Cause%20Mortality.pdf"&gt;MVR study&lt;/a&gt; by RGA actuaries Tim Rozar and Scott Rushing.&lt;/p&gt;

&lt;p&gt;Drunken driving is also substantially implicated in increased odds of hospitalization for a wide range of reasons, including suicide attempts (7.7-fold), drug abuse (16.7-fold) and an alcohol user disorder (16.5-fold). [Karlsson]&lt;/p&gt;

&lt;p style="padding-top: 2em"&gt;&lt;strong&gt;What are the ideal underwriting resources when assessing applicants with a history of DWI/DUI?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Obviously, American underwriters will want a MVR (motor vehicle report) and pharmacy profile (to check for drugs associated with alcoholism and comorbid psychiatric disorders).&lt;/p&gt;

&lt;p&gt;All applicants should routinely be asked about their driving records on teleinterviews, especially at face amounts where MVRs are not routinely ordered…and in all countries where motor vehicle records cannot be obtained for underwriting purposes!&lt;/p&gt;

&lt;p&gt;Elevations of the following tests raise a RED FLAG in this setting:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Isolated GGT&lt;/li&gt;
	&lt;li&gt;AST:ALT ratio ≥ 2.0&lt;/li&gt;
	&lt;li&gt;Markedly elevated HDL-C&lt;/li&gt;
	&lt;li&gt;Elevated mean corpuscular volume (MCV) in medical records&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;In our opinion, all applicants with a history of DWI/DUI within at least 5 – ideally more – years should be required to have a CDT test and if CDT is positive, they should be postponed pending further clinical assessment.&lt;/p&gt;

&lt;p&gt;We also believe that court records should be routinely checked in these cases given the increased prevalence of criminality.&lt;/p&gt;

&lt;p style="padding-top: 2em"&gt;&lt;strong&gt;Does the use of temporary flat extra premiums for DWI/DUI make sense?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In our view, no, because the driver (no pun) of the mortality risk is whether or not the individual has an alcohol use disorder and we use table ratings, not temporary flat extras, for these disorders.&lt;/p&gt;

&lt;p&gt;One might argue for a temporary flat extra in 1st offense cases provided they are devoid of any other significant clues to possible alcohol abuse. However, the latency interval of 6 years between 1st and 2nd DWI/DUI convictions argues against this approach.&lt;/p&gt;

&lt;p&gt;In all other cases, a permanent rating – potentially subject to reconsideration after an extended interval free of further issues – makes more sense to us.&lt;/p&gt;

&lt;p style="padding-top: 2em"&gt;&lt;strong&gt;We hope you found this paper useful.&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;It is presented in the same format as our narrative type &lt;a href="http://www.hankgeorgeinc.com/Testimonial"&gt;Continuing Education Program courses&lt;/a&gt;.&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;For more information about these courses, please visit &lt;a href="http://www.hankgeorgeinc.com" title="www.hankgeorgeinc.com"&gt;www.hankgeorgeinc.com&lt;/a&gt; or contact Esther at esther@hankgeorgeinc.com&lt;/strong&gt;&lt;/p&gt;

&lt;p style="padding-top: 2em"&gt;&lt;strong&gt;References&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Albanese. Journal of Affective Disorders. 121(2010):253&lt;br /&gt;
Baker. Injury Prevention. 8(2002):221&lt;br /&gt;
Bedford. Irish Medical Journal. 102(2009):312&lt;br /&gt;
Blencowe. Therapeutic Drug Monitoring. 33(2011):64&lt;br /&gt;
Beitel. Injury Prevention. 12(2006):158&lt;br /&gt;
Birdsall. Traffic Injury Prevention. 13(2012):24&lt;br /&gt;
Brady. Addiction. 108(2013):104&lt;br /&gt;
Brinkmann. Drug and Alcohol Dependence. 66(2002):7&lt;br /&gt;
Brintzenhoff. American Journal of Surgery. 202(2011):697&lt;br /&gt;
Cavaiola. Addictive Behaviors. 32(2007):855&lt;br /&gt;
Chaudhary. Traffic Injury Prevention. 12(2011):210&lt;br /&gt;
Couture. Accident Analysis and Prevention. 42(2010):307&lt;br /&gt;
Drummer. Forensic Science International. 134(2003):154&lt;br /&gt;
Fell. Annals of Advances in Automotive Medicine. 53(2009):63&lt;br /&gt;
Fell and Tippetts. Traffic Injury Prevention. 11(2010):443&lt;br /&gt;
Freeman. Accident Analysis and Prevention. 43(2011):34&lt;br /&gt;
Furr-Holden. Addiction. 106(2011):1251&lt;br /&gt;
Gjerde. Forensic Science International. 212(2011):102&lt;br /&gt;
Hingson. Alcohol, Research and Health. 27(2003):63&lt;br /&gt;
Hubicka. International Journal of Law and Psychiatry. 31(2008):471&lt;br /&gt;
Karlsson. Alcohol Abuse and Alcoholism. 38(2003):281&lt;br /&gt;
Lapham. Journal of Studies on Alcohol. 67(2006):707&lt;br /&gt;
LaPlante. Journal on Studies of Alcohol and Drugs. 69(2008):209&lt;br /&gt;
Li. Traffic Injury Prevention. 13(2012):101&lt;br /&gt;
Mann. Addiction. 88(1993):642&lt;br /&gt;
Maskalyk. Canadian Medical Association Journal.&lt;br /&gt;
168(2003):313[editorial]&lt;br /&gt;
McMillan. Journal of Substance Abuse Treatment. 34(2008):320&lt;br /&gt;
Miller. Alcoholism: Clinical and Experimental Research. 10(1986):651&lt;br /&gt;
Mortality and Morbidity Weekly Review (MMWR). 53(2004):1103&lt;br /&gt;
Mortality and Morbidity Weekly Review (MMWR). 60(2011):1351&lt;br /&gt;
Ouimet. Accident Analysis and Prevention. 39(2007):743&lt;br /&gt;
Parks. Alcoholism: Clinical and Experimental Research. 20(1996):434&lt;br /&gt;
Pavanello. Alcohol. 46(2012):61&lt;br /&gt;
Peller. Journal of Traumatic Stress. 23(2010):468&lt;br /&gt;
Portman. Drug and Alcohol Dependence. 106(2010):186&lt;br /&gt;
Rao. Forensic Science International. 224(2013):117&lt;br /&gt;
Rauch. Alcoholism: Clinical and Experimental Research. 25,&lt;br /&gt;
Supplement 1(2001):150A&lt;br /&gt;
Romano. Addiction. E-published 4/22/13&lt;br /&gt;
Sansone. Comprehensive Psychiatry. 53(2012):176&lt;br /&gt;
Schermer. Journal of Trauma. 65(2008):1000&lt;br /&gt;
Shaffer. Journal of Consulting and Clinical Psychology. 75(2007):795&lt;br /&gt;
Voss. Alcoholism: Clinical and Experimental Research.&lt;br /&gt;
34(2010):1282&lt;br /&gt;
Wang. International Journal of Occupational Safety and Ergonomics.&lt;br /&gt;
17(2011):155&lt;/p&gt;
&lt;/div&gt;
          &lt;/div&gt;

    &lt;/div&gt;
  &lt;/div&gt;

</description>
  <pubDate>Wed, 31 Jul 2013 14:11:59 +0000</pubDate>
    <dc:creator>hankgeorge</dc:creator>
    <guid isPermaLink="false">25712 at https://rtaylor193.github.io/insureintell-1col</guid>
    </item>
<item>
  <title>Insurability of Former Drinkers</title>
  <link>https://rtaylor193.github.io/insureintell-1col/node/25722</link>
  <description>  &lt;div data-history-node-id="25722" class="layout layout--onecol"&gt;
    &lt;div class="layout__region layout__region--content"&gt;
      
  &lt;div&gt;
    &lt;div&gt;Body&lt;/div&gt;
              &lt;div property="schema:text"&gt;&lt;!--break--&gt;&lt;!--break--&gt;
&lt;style type="text/css"&gt;
&lt;!--/*--&gt;&lt;![CDATA[/* &gt;&lt;!--*/
&lt;!--
.tabletitle {
	text-align: center;
}
--&gt;&lt;!--
.tabletitle {
	text-align: center;
}
--&gt;

/*--&gt;&lt;!]]&gt;*/
&lt;/style&gt;
&lt;p&gt;People stop consuming alcohol for a variety of reasons.&lt;/p&gt;

&lt;p&gt;Some of those reasons – for example, joining a religious group where alcohol use is frowned upon or finally capitulating to nagging by a teetotaling spouse – have no insurability implications.&lt;/p&gt;

&lt;p&gt;&lt;em&gt;Then, there are the others…&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Jürgen Rehm and his coworkers at the Centre for Addiction and Illness in Toronto make this observation regarding non-drinkers:&lt;/p&gt;

&lt;p&gt;&lt;em&gt;“There are at least 2 very distinct groups of abstainers – former drinkers, many of whom have given up drinking for health reasons; and long-term or even lifetime abstainers. For both groups, associations with health outcomes are different.”&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Boston University epidemiologist R. Curtis Ellison affirms this conclusion, comment that:&lt;/p&gt;

&lt;p&gt;&lt;em&gt;“…almost all studies show a higher risk for CHD (as well as most other diseases and total mortality) for recognized ‘ex-drinkers.’ ”&lt;/em&gt;&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Are former drinkers often cigarette smokers&lt;/strong&gt;?&lt;/p&gt;

&lt;p&gt;Numerous studies have shown that robust alcohol consumers are several times more likely to smoke than temperate consumers and lifetime nondrinkers.&lt;/p&gt;

&lt;p&gt;Data from the British Regional Heart Study demonstrate that those who quit alcohol are ill-disposed to giving up their cigarettes:&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;table border="1" width="296"&gt;
	&lt;tbody&gt;
		&lt;tr&gt;
			&lt;td height="42" width="126"&gt;&lt;strong&gt;Drinking Status&lt;/strong&gt;&lt;/td&gt;
			&lt;td width="154"&gt;&lt;strong&gt;% Current Smokers&lt;/strong&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Teetotalers&lt;/td&gt;
			&lt;td&gt;22%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Ex-drinkers&lt;/td&gt;
			&lt;td&gt;39%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Occasional drinkers&lt;/td&gt;
			&lt;td&gt;31%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Light drinkers&lt;/td&gt;
			&lt;td&gt;28%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Moderate drinkers&lt;/td&gt;
			&lt;td&gt;38%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Heavy drinkers&lt;/td&gt;
			&lt;td&gt;48%&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;We should expect a high prevalence of current tobacco use among applicants claiming to have quit drinking. [Wannamethee]&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How do ex-drinkers compare to persons in other alcohol use categories in terms of medical impairments?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;“…recent abstainers are more likely to have stopped because of medical concerns.”&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Marc A Schuckit, MD&lt;br /&gt;
University of California-San Diego Medical School&lt;br /&gt;
Lancet&lt;br /&gt;
373(2009):492&lt;/p&gt;

&lt;p&gt;Former imbibers are considerably more likely to have significant medical histories, as reflected by these findings from a German study: [Wellmann]&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;table border="1" height="247" width="362"&gt;
	&lt;tbody&gt;
		&lt;tr&gt;
			&lt;td class="tabletitle" colspan="5"&gt;&lt;strong&gt;Alcohol Use Status &lt;/strong&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td width="105"&gt; &lt;/td&gt;
			&lt;td width="52"&gt;Never&lt;/td&gt;
			&lt;td width="51"&gt;Former&lt;/td&gt;
			&lt;td width="66"&gt;Temperate&lt;/td&gt;
			&lt;td width="54"&gt;Heavy&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Heart attack&lt;/td&gt;
			&lt;td&gt;10%&lt;/td&gt;
			&lt;td&gt;9%&lt;/td&gt;
			&lt;td&gt;4%&lt;/td&gt;
			&lt;td&gt;2%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Stroke&lt;/td&gt;
			&lt;td&gt;2%&lt;/td&gt;
			&lt;td&gt;4%&lt;/td&gt;
			&lt;td&gt;1%&lt;/td&gt;
			&lt;td&gt;1%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Diabetes&lt;/td&gt;
			&lt;td&gt;5%&lt;/td&gt;
			&lt;td&gt;11%&lt;/td&gt;
			&lt;td&gt;5%&lt;/td&gt;
			&lt;td&gt;3%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Liver disease&lt;/td&gt;
			&lt;td&gt;6%&lt;/td&gt;
			&lt;td&gt;12%&lt;/td&gt;
			&lt;td&gt;3%&lt;/td&gt;
			&lt;td&gt;8%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Stomach disease&lt;/td&gt;
			&lt;td&gt;10%&lt;/td&gt;
			&lt;td&gt;16%&lt;/td&gt;
			&lt;td&gt;7%&lt;/td&gt;
			&lt;td&gt;6%&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;When gerontologists assessed the relative risks of underlying adversities in older age quitters, they discovered some interesting revelations. [Mukamal]&lt;/p&gt;

&lt;p&gt;These individuals were distinguished from teetotalers and currently drinking elders by a number of disconcerting revelations, considering that ex-drinkers had:&lt;/p&gt;

&lt;p&gt;The highest % of diabetics&lt;br /&gt;
The highest % with hypertension&lt;br /&gt;
The greatest prevalence of depression&lt;br /&gt;
The lowest average HDL-C readings&lt;br /&gt;
The highest mean fibrinogen levels&lt;/p&gt;

&lt;p&gt;In addition, older age former alcohol aficionados are 3 times more likely to be disabled than teetotalers and have lower average cognitive scores than persons in all other alcohol use categories. [Lobo]&lt;/p&gt;

&lt;p&gt;The foregoing evidence strongly suggests that many drinkers do indeed quit consuming alcohol because of illness.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Are former alcohol abusers more apt to continue manifesting unfavorable behaviors associated with ongoing alcohol abuse?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;An investigation by experts in automotive medicine tells us that putative ex-drinkers have numerous risk-taking characteristics similar to those prevalent in current abusive drinkers: [Ryb]&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;table border="1" height="236" width="328"&gt;
	&lt;tbody&gt;
		&lt;tr&gt;
			&lt;td class="tabletitle" colspan="4"&gt;&lt;strong&gt;Alcohol Abuse Status&lt;/strong&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td width="142"&gt; &lt;/td&gt;
			&lt;td width="59"&gt;Never&lt;/td&gt;
			&lt;td width="51"&gt;Former&lt;/td&gt;
			&lt;td width="72"&gt;Current&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Not using seat belts&lt;/td&gt;
			&lt;td&gt;48%&lt;/td&gt;
			&lt;td&gt;61%&lt;/td&gt;
			&lt;td&gt;94%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Speeding for thrills&lt;/td&gt;
			&lt;td&gt;5%&lt;/td&gt;
			&lt;td&gt;15%&lt;/td&gt;
			&lt;td&gt;18%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Single vehicle accidents&lt;/td&gt;
			&lt;td&gt;28%&lt;/td&gt;
			&lt;td&gt;35%&lt;/td&gt;
			&lt;td&gt;61%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Conviction for assault&lt;/td&gt;
			&lt;td&gt;9%&lt;/td&gt;
			&lt;td&gt;30%&lt;/td&gt;
			&lt;td&gt;36%&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How do ex-drinkers fare in terms of mortality?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;The first studies documenting that mortality based on alcohol consumption was U-shaped (higher in nondrinkers and heavy drinkers; lowest in temperate consumers) did not make a distinction between teetotalers and ex-drinkers. The result was that alcohol abstention appeared to be a high risk scenario. [Klatsky]&lt;/p&gt;

&lt;p&gt;When these investigators redid their analyses by separating teetotalers from former drinkers, they found that all-cause mortality was indeed favorable in those who never took a drink…&lt;/p&gt;

&lt;p&gt;…and all of the “abstainer” excess death risk fell squarely upon former users.&lt;/p&gt;

&lt;p&gt;There have been numerous assessments of mortality sorted by alcohol use category over the intervening years.&lt;/p&gt;

&lt;p&gt;Let’s look at some of the findings…&lt;/p&gt;

&lt;p&gt;In a 2003 meta-analysis, Gmel and coworkers contrasted mortality in teetotalers to that of ex-users. They found that aggregate mortality was 44% higher in male former drinkers and 21% greater in their female peers.&lt;/p&gt;

&lt;p&gt;Dutch epidemiologists followed 16,210 subjects, ages 45 to 70, for 5 years. They learned that mortality was 74% greater in ex-drinkers as compared to teetotalers, and both nonuser groups fared worse than moderate-to-heavy drinkers. [Friesema]&lt;/p&gt;

&lt;p&gt;Similarly, researchers at the University of Texas Medical School discovered that mortality was 2-fold increased in current nonusers vs. temperate drinkers. Further analysis showed that all of that excess was clustered in the former drinker subset. [Holahan]&lt;/p&gt;

&lt;p&gt;In a study encompassing over 14,000 adults, 5-year mortality was highest in subjects that went from moderate or heavy use to abstention. There was no increase in the risk of death for individuals than continued to consume 14 or more drinks each week. [Grønbek]&lt;/p&gt;

&lt;p&gt;&lt;em&gt;Bottom line?&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Ex-drinkers have higher mortality than teetotalers, temperate drinkers and in some cases even heavy alcohol users.&lt;/p&gt;

&lt;p&gt;The loss of the cardioprotective advantages incurred from alcohol consumption cannot explain these outcomes because for this to be true there would be no significant mortality difference in risk between former and never drinkers.&lt;/p&gt;

&lt;p&gt;Hence, this survival disadvantage associated with discontinuing alcohol use is due to (a) underlying chronic disease and (b) ex-heavy drinkers retaining their other adverse health habits and risk-taking behaviors.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How can underwriters deal effectively with the insidious risk associated with quitting drinking?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;When proposed insureds are asked about alcohol use and they disavow current consumption, ask them if they EVER used alcohol.&lt;/p&gt;

&lt;p&gt;Then, if they affirm prior indulgence, question them further:&lt;/p&gt;

&lt;p&gt;When did you quit drinking?&lt;/p&gt;

&lt;p&gt;Why did you quit drinking?&lt;/p&gt;

&lt;p&gt;&lt;em&gt;Those that cite a specific date for the commencement of abstinence might also be asked what happened the day before!&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;If they quit within, say, the last 5 years…and/or medical, occupational, pharmaceutical, legal or driving record issues…it would be prudent to pursue further evidence of insurability.&lt;/p&gt;

&lt;p&gt;One asset of particular utility in this context is the alcohol marker carbohydrate-deficient transferrin (CDT). If, indeed, they no longer consume alcohol, this test will surely be negative.&lt;/p&gt;

&lt;p&gt;Attending physicians’ records will also be quite illuminating, especially in cases where substantial prior indulgence has (selectively) clouded their memory!&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;References&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Ellison. Annals of Epidemiology. 18,Supplement(2007):1&lt;br /&gt;
Friesema. Journal of Epidemiology and Community Health. 61(2007):441&lt;br /&gt;
Gmel. European Journal of Epidemiology. 18(2007):631&lt;br /&gt;
Grønbek. Epidemiology. 15(2004):222&lt;br /&gt;
Holahan. Alcoholism: Clinical and Experimental Research. 34(2010):1961&lt;br /&gt;
Klatsky. American Journal of Cardiology. 98(2006):1063&lt;br /&gt;
Lobo. American Journal of Epidemiology. 172(2010):708&lt;br /&gt;
Mukamal. Journal of the American Geriatric Society. 54(2006):30&lt;br /&gt;
Rehm. American Journal of Epidemiology. 168(2008):866&lt;br /&gt;
Ryb. 49th Annual Proceedings, Association for the Advancement of Automotive&lt;br /&gt;
Medicine; September, 2005&lt;br /&gt;
Wannamethee. International Journal of Epidemiology. 26(1997):523&lt;br /&gt;
Wellmann. European Journal of Cardiovascular Prevention and Rehabilitation.&lt;br /&gt;
11(2004):48&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;
&lt;/div&gt;
          &lt;/div&gt;

    &lt;/div&gt;
  &lt;/div&gt;

</description>
  <pubDate>Tue, 08 May 2012 18:18:56 +0000</pubDate>
    <dc:creator>hankgeorge</dc:creator>
    <guid isPermaLink="false">25722 at https://rtaylor193.github.io/insureintell-1col</guid>
    </item>
<item>
  <title>Challenging Myths and Rethinking Priorities in Older Age Underwriting: An Essay</title>
  <link>https://rtaylor193.github.io/insureintell-1col/node/25639</link>
  <description>  &lt;div data-history-node-id="25639" class="layout layout--onecol"&gt;
    &lt;div class="layout__region layout__region--content"&gt;
      
  &lt;div&gt;
    &lt;div&gt;Body&lt;/div&gt;
              &lt;div property="schema:text"&gt;&lt;p&gt;&lt;em&gt;&lt;strong&gt;Prologue&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;To determine insurability of applicants age 65 and over on the same basis as we do at younger ages all but guarantees a botched job.&lt;/p&gt;

&lt;p&gt;This is because factors that we know contribute to premature death in young and middle-aged adults differ dramatically from those linked to excess geriatric mortality. These examples give clear evidence of this too-often-overlooked reality.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;
&lt;!--break--&gt;&lt;!--break--&gt;

&lt;p&gt;&lt;strong&gt;ESSAY TEST&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Frailty&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;At younger ages, vitality is a given. Not so in the “golden years,” where the capacity to “merely” carry off routine activities of daily living (ADLs and companion IADLs) has been shown to be a more imposing predictor of survival than diabetes.&lt;/p&gt;

&lt;p&gt;If discussions at my life underwriting study groups reflect industry reality, then only a handful of life companies employ a long-term-care version of the paramedical exam designed to probe physical capacity.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Smoking&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;A number of studies have shown that current tobacco indulgence in the seventh decade and behind translates to very modest extra risk in males and none whatsoever in females. To overemphasize this risk-taking behavior at the expense of other considerations is to mistake the sapling for the forest.&lt;/p&gt;

&lt;p&gt;The emphasis should rightly be on PACK YEARS, not current smoking. And we can derive PACKL YEAR data during the routine TELEINTERVIEW.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Blood Pressure&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;While definite hypertension impacts longevity at all ages, the reality is that its mortality slope becomes distinctly U-shaped late in life. When systolic and/or diastolic readings are too low, the implications are more ominous than when they fall into modestly debited ranges.&lt;/p&gt;

&lt;p&gt;It is a frank shame that we do not yet recognize the sinister nature of high “pulse pressure” (the difference between the systolic and diastolic readings) for what it really means.&lt;/p&gt;

&lt;p&gt;Such a facile calculation.&lt;/p&gt;

&lt;p&gt;Such a potential asset to determining the real risk implications of not only hypertension but “normal” readings as well.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Cholesterol&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;At younger ages, lower is better. Not so later on, when a low or, worse, falling cholesterol (in those not on lipid-lowering Rx, of course) is a proven harbinger of early demise.&lt;/p&gt;

&lt;p&gt;It is time to assign debits – on not minimal ones, to be sure – in situations where the current cholesterol is low (&lt;140 mg/dL) in the absence of Rx. If it is falling from a previous high level, the risk is worse. If the serum albumin is low, the risk is multiplicative at best. Ditto for an HDL &lt; 30 mg/dL.&lt;/p&gt;

&lt;p&gt;And if the total cholesterol is extremely low (&lt; 100 mg/dL), accompanied by very low triglycerides and very low HDL-C, this raises the specter of cirrhosis. Take another look at ALL the liver-related tests – and don’t be dissuaded from pursing the issue if the aminotransferases (ALT, AST) happen to be normal or minimally elevated.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Heavy Drinking &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Abuse of alcohol is worrisome at all ages. However, three distinct realities must be born in mind when assessing its impact over age 65:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;First, the elderly are far less tolerant of alcohol’s acute effects, so that what we consider “social drinking” at age 40 confers genuine risk three decades later.&lt;/li&gt;
	&lt;li&gt;A second consideration is the synergy of alcohol intake and medication effects.&lt;/li&gt;
	&lt;li&gt;Two beers and the wrong pill – which may have been correctly prescribed for the right reason – can beget the fall that begets the hip fracture that begets fearsome short-duration mortality.&lt;/li&gt;
	&lt;li&gt;Lastly, our elders are quite adept at “hiding the bottle!” Woe betides he who discounts even equivocal laboratory and medical history clues to overindulgence in the geriatric risk population.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Diabetes &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;One of the most disturbing deviations from good underwriting is our rampant failure to appreciate the implications of diabetes at all ages. It is axiomatic in studies of virtually all impairments that the diabetic will fare far worse than those with normal glucose metabolism. This becomes proportionally more important over age 65, as the incidence of diabetes rises and some other prominent cardiovascular risk factors lose much of their impact.&lt;/p&gt;

&lt;p&gt;In this underwriter’s view, the pretense of the “preferred diabetic” is one of our most ill-conceived oxymorons!&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Build &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;The mortality of “build” is distinctly U-shaped at older ages. So much so that one could make a convincing argument for underweight being the real issue. Nevertheless, we continue to measure this risk solely in terms of weight in relation to height. A two-inch-thick stack of research studies proves that it isn’t “how much you carry” but “where you carry it” that makes all the difference. How many well-heeled, pleasingly plump elderly ladies are unwitting victims of our failure make use of the waist-to-hip ratios, the best benchmark where obesity is concerned.&lt;/p&gt;

&lt;p&gt;This underwriter remains flummoxed by the assertion by some that waist-to-hip ratios cannot be measured during routine paramedicals. Think of the value they might add in the aforementioned scenario!&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Rx Use &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Older people take more medications than their offspring. Indeed, this phenomenon has earned the label “polypharmacy.” In some cases – use of benzodiazepine sedatives like Valium® being a clear example – the implications of drug effects may translate to risks all too often unappreciated.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;em&gt;&lt;strong&gt;Epilogue &lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;These are just a few examples of how older age underwriting is more distinctive than many prevailing underwriting practices recognize.&lt;/p&gt;

&lt;p&gt;Has the time come for this knowledge to be translated into new geriatric risk paradigms?&lt;/p&gt;

&lt;p&gt;Is the PREFERRED geriatric risk distinctly different from the PREFERRED applicant in midlife (and that individual, in turn, distinctly different from the 18-39 year old)?&lt;/p&gt;

&lt;p&gt;Do we not, in fact, have three distinctive subsets of PREFERRED?&lt;/p&gt;

&lt;p&gt;This underwriter does not hesitate to offer up his emphatic YES to these questions.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;
&lt;/div&gt;
          &lt;/div&gt;

    &lt;/div&gt;
  &lt;/div&gt;

</description>
  <pubDate>Wed, 23 Sep 2009 13:01:09 +0000</pubDate>
    <dc:creator>hankgeorge</dc:creator>
    <guid isPermaLink="false">25639 at https://rtaylor193.github.io/insureintell-1col</guid>
    </item>
<item>
  <title>Serum Hyaluronic Acid (HA): A Potential Reflexive Test for Further Evaluating Individuals with Chronic Hepatitis B and C, NASH and Other Liver Pathologies</title>
  <link>https://rtaylor193.github.io/insureintell-1col/node/25638</link>
  <description>  &lt;div data-history-node-id="25638" class="layout layout--onecol"&gt;
    &lt;div class="layout__region layout__region--content"&gt;
      
  &lt;div&gt;
    &lt;div&gt;Body&lt;/div&gt;
              &lt;div property="schema:text"&gt;&lt;p&gt;&lt;strong&gt;Why am I writing this paper?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In underwriting, we are seeing an increasing number of cases of chronic hepatitis C and nonalcoholic fatty liver disease (especially nonalcoholic steatohepatitis, NASH) wherein the proposed insured has not had a sufﬁcient clinical workup to determine if advanced liver pathology (signiﬁcant ﬁbrosis, cirrhosis) is present.&lt;/p&gt;

&lt;p&gt;This is a key determination regarding insurability and the absence of this information has forced us to take uncertain actions…certainly insuring some who are bad risks while postponing others who are insurable.&lt;/p&gt;

&lt;p&gt;Serum hyaluronic acid (also known as hyaluronate, hyaluron or simply HA) appears to be a potentially affordable marker for the noninvasive detection of high grade ﬁbrosis and cirrhosis in these and other liver pathologies.&lt;/p&gt;
&lt;!--break--&gt;&lt;!--break--&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is the clinical perspective on this issue? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;“Progressive hepatic ﬁbrosis with the development of cirrhosis is a feature of almost all chronic liver diseases.” &lt;/em&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;Nezam H. Afdahl&lt;br /&gt;
Chief of Hepatology&lt;br /&gt;
Harvard Medical School&lt;br /&gt;
&lt;em&gt;The American Journal of Gastroenterology&lt;/em&gt;&lt;br /&gt;
99,6(2004):1160-74&lt;/p&gt;
&lt;/blockquote&gt;

&lt;p&gt;&lt;em&gt;“One of the major problems facing the hepatology and gastroenterology community is how to best evaluate and manage the increasing numbers of patients with hepatitis C virus… However, little progress has been made in improving either our ability to determine the degree of hepatic injury, particularly ﬁbrosis, or to predict the risk of disease progression for the individual patient. This information still requires an old fashioned liver biopsy.” &lt;/em&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;Nezam H. Afdahl&lt;br /&gt;
“Diagnosing Fibrosis in Hepatitis C: Is the Pendulum Swinging From Biopsy to Blood Tests?”&lt;br /&gt;
Editorial&lt;br /&gt;
&lt;em&gt;Hepatology &lt;/em&gt;&lt;br /&gt;
37,5(2003):972-4&lt;/p&gt;
&lt;/blockquote&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Are there a number of alternative choices out there for this role? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes, several multi-test protocols have been recommended, such as a panel dubbed FIBROTEST. However, these proﬁles require as many as 5 or more test components, some of which may be expensive or difﬁcult to access for our purposes.&lt;/p&gt;

&lt;p&gt;Of all the individual markers feasible for our purposes, HA appears to be the best.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is the basic viewpoint on HA held by its advocates? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;“Serum HA is currently the best available marker of hepatic ﬁbrogenesis.” &lt;/em&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;Jacob George&lt;br /&gt;
University of Sydney&lt;br /&gt;
New South Wales, Australia&lt;br /&gt;
Editorial&lt;br /&gt;
&lt;em&gt;Journal of Gastroenterology and Hepatology &lt;/em&gt;&lt;br /&gt;
15(2000):819-21&lt;/p&gt;
&lt;/blockquote&gt;

&lt;p&gt;&lt;em&gt;“The greatest clinical utility of HA may be its ability to exclude patients with signiﬁcant ﬁbrosis and cirrhosis….an HA level of &lt; 60 ng/L was found to exclude patients with cirrhosis and signiﬁcant hepatic ﬁbrosis with predictive values of 99% and 93%, respectively.&lt;/em&gt;”&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;Nezam H. Afdhal&lt;br /&gt;
&lt;em&gt;The American Journal of Gastroenterology &lt;/em&gt;&lt;br /&gt;
99,6(2004):1160-74&lt;/p&gt;
&lt;/blockquote&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is HA? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;It is a protein, manufactured by liver stellate cells and “is considered to be a factor contributing to ﬁbrogenesis…the increase in HA production may reﬂect the…the synthesis of extrecellular matrix due to inﬂammation.” (1)&lt;/p&gt;

&lt;p&gt;“Elimination of hyaluronic acid from the circulation is a speciﬁc receptor-mediated mechanism on hepatic sinusoidal endothelial cells. These specialized cells are thought to play an important role in the maintenance of liver function.” (2)&lt;/p&gt;

&lt;p&gt;In other words, it plays a key role in setting the stage for cirrhosis.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How is HA measured? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In serum.&lt;/p&gt;

&lt;p&gt;There are several methods reported, including radioimmunoassay (RIA) and sandwich ELISA.&lt;/p&gt;

&lt;p&gt;RIA involves the handling of radioactive materials and is being phased out.&lt;/p&gt;

&lt;p&gt;We use an ELISA test now for HIV-1 screening, so this methodology has been deemed affordable in our realm.&lt;/p&gt;

&lt;p&gt;This underwriter has tried to track down prevailing prices for performing HA clinically, only to discover that it is not readily available (perhaps not available at all) from clinical labs in the United States (3) However, it is available, and apparently used regularly, in Germany and perhaps elsewhere in Europe. (4)&lt;/p&gt;

&lt;p&gt;I will continue this effort to get more information on testing methodologies and projected costs.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Are there special considerations that limit this test? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Not that I have discovered thus far.&lt;/p&gt;

&lt;p&gt;There was a question of the testing being superior when done fasting, but another paper maintains that post-prandial testing is adequate. (5)&lt;/p&gt;

&lt;p&gt;HA is not affected by pregnancy. It also does not appear to vary by patient age. (6) However, we have no information as yet regarding the potential impact of smoking, obesity (which is a prevalent component in nonalcoholic fatty liver disease), exercise and other potential confounders.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does HA correlate with disease progression? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes.&lt;/p&gt;

&lt;p&gt;Xu et al. in Shanghai report that HA levels increased with progression of ﬁbrosis-to-cirrhosis. (7)&lt;/p&gt;

&lt;p&gt;It does not appear that HA correlates with necroinﬂammatory disease, only with its sequelae (ﬁbrosis and cirrhosis). On the other hand, the aminotransferases (ALT, AST) are more reliable in the inﬂammation and cell death phases of chronic liver disease than they are as markers for ﬁbrosis and cirrhosis, so HA would seem to be a logical potential reﬂexive test for subjects with elevated aminotransferases who have proven or strongly suspected chronic liver pathology.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What do we know so far about HA in chronic hepatitis C? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;A good amount, based on clinical studies of cohorts of HCV patients:&lt;/p&gt;

&lt;p&gt;&lt;em&gt;“In chronic hepatitis C, serial hyaluronic acid levels have been advocated as a means to monitor disease progression and to limit the need for follow-up biopsy.” &lt;/em&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;Martin G. Phillips&lt;br /&gt;
Department of Gastroenterology&lt;br /&gt;
Norfolk and Norwich University Hospital, UK&lt;br /&gt;
&lt;em&gt;European Journal of Gastroenterology and Hepatology &lt;/em&gt;&lt;br /&gt;
15(2003):941-44&lt;/p&gt;
&lt;/blockquote&gt;

&lt;p&gt;Guechot (Paris) evaluated 326 untreated HCV patients. They found HA superior to other markers. Sensitivity was 64.5% and speciﬁcity was 91.2% for discriminating signiﬁcant ﬁbrosis from no ﬁbrosis/mild ﬁbrosis. For cirrhosis, sensitivity was 79.2% and speciﬁcity was 89.4%. The authors concluded that “HA should be preferred when monitoring liver ﬁbrosis in patients with chronic viral hepatitis C.” (8)&lt;/p&gt;

&lt;p&gt;Wong (UK) looked at 130 asymptomatic HCV carriers (a risk we often see, if only by inference). ALT had no correlation with ﬁbrosis/cirrhosis. HA levels went from means of 17 in stages 1 + 2 ﬁbrosis to 30 in stage 3 and 350 in stage 4 and cirrhosis, using their criteria. They advocated using HA “…to monitor patients at risk for progressive ﬁbrosis…” (9)&lt;/p&gt;

&lt;p&gt;McHutchinson (Scripps Clinical, California) followed 486 chronic HCV patients.&lt;/p&gt;

&lt;p&gt;Predictive values were in the 90%+ range. For ﬁbrosis, mean values were 179 micrograms/L if present and 62 if absent. For cirrhosis, 382 if present and 110 if absent. Both had p values of 0.001, which means these are highly signiﬁcant differences. (10)&lt;/p&gt;

&lt;p&gt;Murakawi (Japan) tested 169 chronic HCV patients and found HA to be the #1 test in terms of “…grading patients in chronic hepatitis C.” Using a cut-off of 60 ng/mL provided a sensitivity of 77% and a speciﬁcity of 74%. (11)&lt;/p&gt;

&lt;p&gt;Jara (University of Miami) compared 130 subjects with chronic HCV to 50 controls:&lt;/p&gt;

&lt;table border="1" width="200"&gt;
	&lt;tbody&gt;
		&lt;tr&gt;
			&lt;td&gt; &lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;ng/mL&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Controls&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;24&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Stage 1 ﬁbrosis&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;40&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Stage 2 ﬁbrosis&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;32&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Stage 3 ﬁbrosis&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;99.7&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Cirhosis&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;331.5&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;An HA &lt; 70 excluded 96% of cases free of advanced (stage 3) ﬁbrosis or cirrhosis. (12)&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How does HA function in cases of medically-treated chronic HCV? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;On balance, as well as in untreated cases (above).&lt;/p&gt;

&lt;p&gt;Guechot (Paris) followed 52 patients before and after interferon therapy. (13)&lt;/p&gt;

&lt;ol&gt;
	&lt;li&gt;If ﬁbrosis progressed, HA rose signiﬁcantly&lt;/li&gt;
	&lt;li&gt;If ﬁbrosis regressed, HA fell&lt;/li&gt;
	&lt;li&gt;If ﬁbrosis remained stable, so did HA&lt;/li&gt;
	&lt;li&gt;ALT had absolutely no correlation with ﬁbrosis/cirrhosis&lt;/li&gt;
&lt;/ol&gt;

&lt;p&gt;Ishibashi (Japan) found that HA reached normal levels within a year in subjects in sustained complete remission after Rx. (14)&lt;/p&gt;

&lt;p&gt;Patel (Duke University Medical School, US) reported that sustained virological responders had “a signiﬁcantly reduced HA compared to non-responders.” (15)&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How does HA stack up in chronic hepatitis B (HBV)? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Chen (Guangzhou, China) tested 350 chronic HBV patients and said that HAA was “…the best marker for diagnosing compensated liver cirrhosis.” He and his colleagues tested 350 subjects and a cutoff of 119 ng/mL provided a sensitivity of 87% and a speciﬁcity of 68%, with a 95% negative predictive value. (16)&lt;/p&gt;

&lt;p&gt;Portuguese researchers looked at 111 consecutive chronic HBV carriers (a scenario we encounter often) and found that “…serum hyaluron concentration correlates with hepatic ﬁbrosis…” (17)&lt;/p&gt;

&lt;p&gt;Park in Korea reported on 100 cases of chronic HBV, wherein a cutoff of 77 ng/mL had a sensitivity of 81% and a speciﬁcity of 87% as a marker for ﬁbrosis or worse. (18)&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What was discovered in studies with patients who have a mixture of chronic liver diseases? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Ramadori (Germany) examined 133 patients with various chronic liver pathologies, as compared to 22 with acute hepatitis and 50 disease-free controls.&lt;/p&gt;

&lt;p&gt;HA was elevated in 32% with chronic active hepatitis C and 91% with proven cirrhosis. It was also elevated in the patients with acute hepatitis (whom we would postpone), but not in the controls. They found the HA results to be statistically signiﬁcant. (19)&lt;/p&gt;

&lt;p&gt;Murakawi (Japan) used the sandwich ELISA in 115 chronic hepatitis patients. HAA levels were closely correlated with the severity of ﬁbrosis. HA was the best performing of the ﬁbrosis markers they studied. (20)&lt;/p&gt;

&lt;p&gt;Oberti (France) evaluated 243 patients with chronic liver disease. At a cutoff of &gt; 59 ng/mL, HA had a sensitivity of 97% and a speciﬁcity of 73% for compensated cirrhosis and it was labeled “…the most sensitive screening variable for screening.” (21)&lt;/p&gt;

&lt;p&gt;Plevris (Scotland) evaluated 221 patients with various chronic liver pathologies.&lt;/p&gt;

&lt;p&gt;This is how the mean levels of HA turned out: (22)&lt;/p&gt;

&lt;table border="1" width="305"&gt;
	&lt;tbody&gt;
		&lt;tr&gt;
			&lt;td width="223"&gt;&lt;strong&gt;Pathology&lt;/strong&gt;&lt;/td&gt;
			&lt;td width="66"&gt;
			&lt;div align="center"&gt;&lt;strong&gt;HA (ng/mL) &lt;/strong&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Cirrhosis&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;440&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Fibrosis&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;144&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Fatty Liver&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;107&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Necroinﬂammatory disease only&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;63&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;To avoid redundancy, we will not cite two additional papers wherein the same results were shown. (23)&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is HA effective in NASH? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;“HA had a signiﬁcant positive correlation with the stage of ﬁbrosis in patients with NASH. Serum HA increased the level of prediction when added to an existing liver diagnostic model for the presence of severe ﬁbrosis.” &lt;/em&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;Ayako Suzuki&lt;br /&gt;
Mayo Clinic&lt;br /&gt;
&lt;em&gt;Hepatology &lt;/em&gt;&lt;br /&gt;
34,4,Supplement 1(2003):503A(abstract #715)&lt;/p&gt;
&lt;/blockquote&gt;

&lt;p&gt;Hashimoto (Tokyo) found that a cut-off of 51 ng/mL provided a sensitivity of 88% and a speciﬁcity of 97% in distinguishing grades 3 and 4 ﬁbrosis from subjects with lesser degrees of liver damage in nonalcoholic fatty liver disease. (24)&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Although most cases of primary biliary cirrhosis are uninsurable, does HA serve a useful purpose here, too? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Absolutely.&lt;/p&gt;

&lt;p&gt;Guechot (Paris) found a strong correlation between degree of ﬁbrosis, as did both Nyberg (Sweden) and Remmel (Estonia). (25)&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is there an equally strong link between HA and advanced chronic alcoholic liver disease? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Every bit as strong.&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;"…serum hyaluronic acid increases at an early stage of ALD, rising continuously as liver disease progresses. Because of its tight correlation with the degree of ﬁbrosis and a high sensitivity for detecting early histological changes due to alcohol, serum hayluronic acid concentrations should be considered an important marker for noninvasive prediction of ﬁbrosis and ﬁnally cirrhosis in alcoholics.”&lt;/em&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;Flex Stickel et al.&lt;br /&gt;
University of Erlangen-Nuremberg&lt;br /&gt;
Germany&lt;br /&gt;
&lt;em&gt;European Journal of Gastroenterology and Hepatology &lt;/em&gt;&lt;br /&gt;
14(2003):945-50&lt;/p&gt;
&lt;/blockquote&gt;

&lt;p&gt;Pares reports an excellent correlation, paralleling extent of liver damage in 45 chronic alcoholics in Barcelona. (26)&lt;/p&gt;

&lt;p&gt;Tsutusami (Japan) discovered that “serum HA concentrations in patients actively drinking with ALD were signiﬁcantly higher (p &lt;0.001) than those with non-ALD.” After 4 weeks abstinence, the HA values normalized. (27)&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does HA have any association with non-liver diseases of interest to us in underwriting? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;I found one study where HA was of use in detecting progression of disease in a cohort of 82 patients with rheumatoid arthritis. The authors said that “baseline HA level correlated with measures of disease activity, including swollen and tender joints…ESR, CRP…” After a year, those who developed joint erosions has signiﬁcantly higher levels. (28)&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does this link between liver disease and RA compromise its use in underwriting? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Not really. We should be able to distinguish the RA cases…and RA is probably underpriced in most manuals!&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does one assessment sum up these ﬁndings? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Try this one:&lt;/p&gt;

&lt;p&gt;Christophe Pilette et al. in France compared available ﬁbrosis markers. In 243 patients with chronic liver diseases, they found the correlations of all other tests were inferior to the correlation of HA, concluding their paper by saying that “hyaluronate is the serum marker which is the most highly correlated with liver ﬁbrosis.” (29)&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How do the statistical benchmarks (sensitivity, speciﬁcity, positive and negative predictive values) sort in terms of the potential underwriting value of HA? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;The answer lies in what we do.&lt;/p&gt;

&lt;p&gt;We sort risks.&lt;/p&gt;

&lt;p&gt;We do not make diagnoses or treat the sick!&lt;/p&gt;

&lt;p&gt;If we could rule out the presence of uninsurable degrees of ﬁbrosis and the presence of cirrhosis, we would be better able to assess risk. Clearly, the negative predictive values cited above are very encouraging in this regard.&lt;/p&gt;

&lt;p&gt;This point is made by Phillips from a clinical perspective:&lt;/p&gt;

&lt;p&gt;&lt;em&gt;“…a low hyaluronic acid level in combination with a low clinical probability of ﬁbrotic disease could reassure clinicians that a biopsy is not required.” (30) &lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Our existing alternatives – basically, the aminotransferases – are incredibly inferior to HA in terms of separating these risks in the absence of (recent) biopsy on an MD report.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How might we use HA in underwriting, assuming it is available and affordable? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;It is NOT a suitable candidate for a screening test.&lt;/p&gt;

&lt;p&gt;At least one major company has shown that screening for hepatitis C has signiﬁcant protective value. Being able to get a handle on the extent of disease in screened cases would allow us to postpone the worst cases for further clinical assessment and perhaps make offers on the remainder.&lt;/p&gt;

&lt;p&gt;HA would be the PERFECT “conﬁrmatory” test when we have a positive anti-HCV or Hepatitis B surface antigen in subjects reﬂexed due to liver enzyme elevations. By doing serology and HA, we would be better able to integrate the ﬁndings with what else is known and make better offers wherever possible.&lt;/p&gt;

&lt;p&gt;We have nothing at this time to get a ﬁrm underwriting handle on the rising number of nonalcoholic liver disease cases unless – as is the distinct exception – a biopsy is done. This is especially true for the most advanced state within this category, better known as NASH. The AST:ALT ratio helps in this regard but it would be enhanced with HA testing on the same specimen.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is the next step? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Petition the industry labs to further investigate the potential for using HA as a reﬂexive test, especially as regards:&lt;/p&gt;

&lt;ol&gt;
	&lt;li&gt;The availability of technology (which should not be a problem if the test is done widely in Germany)&lt;/li&gt;
	&lt;li&gt;Whether the test can be done in-house or would have to be shipped out to a specialty lab&lt;/li&gt;
	&lt;li&gt;Assuming the test can be done, determining at what price it could be made available as a reﬂexive test&lt;/li&gt;
&lt;/ol&gt;

&lt;p&gt;I hope you found this to be of some interest.&lt;/p&gt;

&lt;p&gt;Maybe we have something here.&lt;/p&gt;

&lt;h5&gt;1. Znoiko and Yuschuk. Current Pharmaceutical Biotechnology. 4(2003):195-209&lt;br /&gt;
2. Phillips et al. European Journal of Gastroenterology and Hepatology. 15(2003):941-44&lt;br /&gt;
3. Personal communications with Dr. Sandy Lowden (LabOne Canada) and Dr. Pamela Bean (Rogers Memorial Hospital, Oconomowoc, Wisconsin)&lt;br /&gt;
4. Personal communication with Dr. Felix Stickel (University of Erlangen-Nurenberg, Germany)&lt;br /&gt;
5. Idobe. Internal Medicine. 37,7(July, 1998):568-75&lt;br /&gt;
6. Lindqvist and Laurent. Scandinavian Journal of Clinical Laboratory Investigation. 52,7(November, 1992):613-21&lt;br /&gt;
7. Xu et al. Hepatobiliary and Pancreatic Disease Investigation. 1,2(May 2002):246-48&lt;br /&gt;
8. Guechot et al. Clinical Chemistry. 42,4(April, 1996):558-63&lt;br /&gt;
9. Wang et al. Journal of Viral Hepatology. 5,3(May, 1998):187-92&lt;br /&gt;
10. McHutchinson et al. Journal of Gastroenterology and Hepatology. 15,8(August, 2000):945-51&lt;br /&gt;
11. Murawaki et al. Journal of Gastroenterology. 36,6(2001):399-406&lt;br /&gt;
12. Jara et al. Hepatology. 40,4,Supplement 1(2004):687A (abstract #1200)&lt;br /&gt;
13. Guechot et al. Journal of Hepatology. 22,1(January, 1995):22-6&lt;br /&gt;
14. Ishibashi et al. Hepatology. 24,1(July, 1996):23-31&lt;br /&gt;
15. Patel et al. Journal of Gastroenterology and Hepatology. 18,3(March, 2003):253-7&lt;br /&gt;
16. Zhonghua et al. Gan Zang Bing Za Zhi [journal in Chinese; translation of abstract obtained]11,4(April, 2003):225-7&lt;br /&gt;
17. Pontinha et al. Scandinavian Journal of Clinical Laboratory Investigation. 59,5(August, 1999):343-7&lt;br /&gt;
18. Park et al. Tachan Kan Hakkoe Chi [journal in Korea; translation of abstract obtained] 9,2(June, 2003):79-88&lt;br /&gt;
19. Ramadori et al. European Journal of Clinical Investigation. 21,3(June, 1991):323-30&lt;br /&gt;
20. Murawaki. Journal of Gastroenterology and Hepatology. 11,5(May, 1996):459-65&lt;br /&gt;
21. Oberti et al. Gastroenterology. 113,5(November, 1997):1609-16&lt;br /&gt;
22. Plevris et al. European Journal of Gastroenterology and Hepatology. 12,10(October, 2000):1121-7&lt;br /&gt;
23. Xie et al. Hepatobiliary and Pancreatic Disease Investigation. 2,1(February, 2003):69-72; Kim. Korean Journal of Gastroenterology [journal in Korean; translation of abstract obtained]. 42,6(December, 2003):510-8&lt;br /&gt;
24. Suzuki et al. Hepatology. 34,4,Supplement 1(2003):503A(abstract #715); Kenada. Hepatology 40,4,Supplement 1(2004):588A (abstract #981)&lt;br /&gt;
25. Geuchot et al. Journal of Hepatology. 20,3(March, 1994):388-93; Nyberg et al. Journal of Internal Medicine. 231,5(May, 1992):485-91; Remmel et al. Journal of Gastroenterology and Hepatology. 11,11(November, 1996):1016-20&lt;br /&gt;
26. Pares et al. Hepatology. 24,6(December, 1996):1399-403&lt;br /&gt;
27. Tsutsumi et al. Alcoholism Clinical and Experimental Research. 21,9(December, 1997):1716-21&lt;br /&gt;
28. Majeed et al. Annuals of Rheumatologic Diseases. 63,9(September, 1004):1166-8&lt;br /&gt;
29. Pilette et al. Journal of Hepatology. 28(1998):439-46&lt;br /&gt;
30. Phillips et al. op. cit.&lt;/h5&gt;
&lt;/div&gt;
          &lt;/div&gt;

    &lt;/div&gt;
  &lt;/div&gt;

</description>
  <pubDate>Wed, 23 Sep 2009 13:01:09 +0000</pubDate>
    <dc:creator>hankgeorge</dc:creator>
    <guid isPermaLink="false">25638 at https://rtaylor193.github.io/insureintell-1col</guid>
    </item>
<item>
  <title>Ethyl Glucuronide (EtG): Does it Bring Significant Value as an Underwriting Test?</title>
  <link>https://rtaylor193.github.io/insureintell-1col/node/25656</link>
  <description>  &lt;div data-history-node-id="25656" class="layout layout--onecol"&gt;
    &lt;div class="layout__region layout__region--content"&gt;
      
  &lt;div&gt;
    &lt;div&gt;Body&lt;/div&gt;
              &lt;div property="schema:text"&gt;&lt;p&gt;&lt;strong&gt;Background&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Alcohol overuse – often but not always identified as “abuse” – and alcohol dependency (alcoholism, a disease) have been insidiously associated with substantial excess mortality – going back to an excellent study by Lincoln National Re in the late 1970s if not before – and well as fulminant excess morbidity.&lt;/p&gt;

&lt;p&gt;With the introduction of widespread screening with blood profiles in the mid-1980s, we obtained the results of the gamma-glutamyltransferase (GGT) test on a vast number of insurance applicants. This test has a well-known and profusely-documented association with heavy drinking. In addition, we also had the results of two other tests associated, albeit less strongly so, with alcohol excess, HDL-C and AST (especially when the AST:ALT ratio is significantly elevated).&lt;/p&gt;
&lt;!--break--&gt;&lt;!--break--&gt;

&lt;p&gt;In the ensuing years, two “alcohol markers” were embraced by North American insurers to serve as reflexive tests, ordered when one or more of these screening markers was elevated, as well as in other contexts suspicious for alcohol abuse.&lt;/p&gt;

&lt;p&gt;One of them, CDT (carbohydrate-deficient transferrin), is far more widely used by underwriters. It is also used clinically and in other applications outside medical care. The other test, HAA (hemoglobin-associated acetaldehyde), is still used by some, although there are issues about it which have yet to be addressed (in spite of this underwriter’s efforts to get them aired out).&lt;/p&gt;

&lt;p&gt;As underwriters, we have always yearned for a “magical bullet” which could reliably distinguish excess alcohol intake, free of significant numbers of false-positives and false-negatives. In this way we share a common dilemma with clinical medicine. However, the nature of our needs differs from those of physicians, and some of the assets they deploy in this regard (blood alcohol, diagnostic questionnaires related to heavy drinking, etc.) are either not accessible to us or of little value in our setting.&lt;/p&gt;

&lt;p&gt;Recently, another test has been advanced by some as having value in the risk appraisal process. Known as ethyl glucuronide, or EtG for short, it can apparently be performed on a reliable and affordable basis in underwriting.&lt;/p&gt;

&lt;p&gt;The question which remains to be addressed is whether it brings sufficient value as an underwriting resource to justify the expense and other issues inherent in embracing it in our work. This is the question to be explored in this short paper.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;The Ethyl Glucuronide Test&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is ethyl glucuronide (EtG)? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;It is a chemical formed when a tiny fraction of alcohol ingested is processed for excretion.&lt;/p&gt;

&lt;p&gt;Most alcohol is processed via the so-called oxidative, or alcohol dehydrogenase, pathway. The remaining 5% is either excreted unchanged in the urine and sweat, or via exhalation; or metabolized by a non-oxidative pathway. It is this latter pathway which results in the presence of EtG in urine, blood and other mediums where its presence can be measured.&lt;/p&gt;

&lt;p&gt;As a marker for recent alcohol intake, EtG is far superior to blood or urine alcohol levels because it has a much longer elimination period. Thus, a positive EtG test provides significant evidence of recent alcohol consumption even when alcohol is no longer present in the body.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What method is used to measure EtG? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;According to Dr. Pamela Bean, an expert in this field, the test is best done on urine using an enzyme immunoassay which, when positive, is confirmed using liquid chromatography with mass spectrometry (a confirmation technique similar to what we use for drugs of abuse).&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How long after last use can alcohol intake be detected using EtG? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;After reviewing the literature on EtG, we find a number of differing answers.&lt;/p&gt;

&lt;p&gt;In a cohort of alcoholics in detoxification, Beck et al. were able to detect EtG in urine for 65 hours after last apparent intake.&lt;/p&gt;

&lt;p&gt;Skipper et al., in Alabama, report “an extended window for assessment of drinking status (up to 5 days)” with EtG.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How soon after alcohol intake can EtG be detected in urine? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Dahl and his Swedish coworkers found detectable EtG one hour after consumption of one beer.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;At what daily level of alcohol intake is EtG positive in healthy people? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In a cohort of healthy volunteers, Borucki and his colleagues reported a positive EtG level in healthy subjects free of known alcohol abuse who consumed an average of 36 grams of alcohol per day.&lt;/p&gt;

&lt;p&gt;In males, 36 g/day is less than half of the threshold most widely-recognized as defining “abuse” (80 or more g/day).&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How soon after alcohol take have researchers found false-negative EtG readings? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Using a commercial EtG assay, Wojcik and Hawthorne had negative ETG results on all subjects at &gt; 26 hours after drinking.&lt;/p&gt;

&lt;p&gt;Helander et al. reported EtG false-negatives as early as 24 hours. After 5 days of storage, urine EtG was only detectable in 50% that were positive on day one.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Can heavy water intake prior to collecting a urine sample for EtG testing cause a false-negative? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes. [Dahl]&lt;/p&gt;

&lt;p&gt;Are there any causes of false-positive EtG tests that could be significant in an underwriting context?&lt;/p&gt;

&lt;p&gt;Yes, and quite a number of them, actually:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Gargling with mouthwash containing 12% ethanol [Costantino]&lt;/li&gt;
	&lt;li&gt;Cough syrup [Wurst]&lt;/li&gt;
	&lt;li&gt;Purell hand sanitizers [Bean]&lt;/li&gt;
	&lt;li&gt;Food products containing cooking wines and vanilla extracts [Bean]&lt;/li&gt;
	&lt;li&gt;The over-the-counter remedies sold as NyQuil® and Vicks® [Bean]&lt;/li&gt;
	&lt;li&gt;Several beauty products [Bean]&lt;/li&gt;
	&lt;li&gt;Urinary tract infection due to E. coli [Bean]&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Are there any other factors that can distort the results of EtG tests? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes: [Wurst and Wiesbeck]&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Marijuana use&lt;/li&gt;
	&lt;li&gt;Chronic kidney disease&lt;/li&gt;
	&lt;li&gt;Elevated creatinine independent of a diagnosis of CKD&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;What is the main perceived value of EtG? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;“…if the question of recent alcohol consumption is to be answered in a dichotomous way (yes/no), like for the question of lapses or in persons who have committed to abstinence (e.g., physician health care programs), the cumulative data support the use of the test for EtG in urine.” &lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Friedrich Martin Wurst, et al.&lt;br /&gt;
&lt;em&gt;Alcoholism: Clinical and Experimental Research &lt;/em&gt;&lt;br /&gt;
28(2004):1220&lt;/p&gt;

&lt;p&gt;Thus, EtG can, save for a few false-negatives, rule out recent drinking within some window period of detection.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What use is postulated for EtG in a clinical context? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;“We use this test all the time. It is the best test we have for measuring recent use. When patients leave our facility for a few days, when they come back, we obtain an EtG…” &lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Paul H. Earley, MD (as cited by Bob&lt;br /&gt;
Littell, based on an interview)&lt;br /&gt;
&lt;em&gt;Broker World &lt;/em&gt;&lt;br /&gt;
November, 2007:40&lt;/p&gt;

&lt;p&gt;&lt;em&gt;“…it is possible to refute a claimed alcohol abstinence by a positive EtG in blood, urine, skin, swab or hair – with a reliability greater than was provided previously by ethanol.” &lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Stephen Seidl et al.&lt;br /&gt;
Institute of Legal Medicine&lt;br /&gt;
University of Erlangen, Germany&lt;br /&gt;
&lt;em&gt;Addiction Biology&lt;/em&gt;&lt;br /&gt;
6(2001):205&lt;/p&gt;

&lt;p&gt;Wurst and Skipper identify the following settings in which they believe EtG would have value:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Alcohol treatment programs&lt;/li&gt;
	&lt;li&gt;Safety-sensitive work settings&lt;/li&gt;
	&lt;li&gt;Other settings where alcohol use may be risky (pregnancy, etc.)&lt;/li&gt;
	&lt;li&gt;Forensic assessments&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Is there any way to enhance EtG testing? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes, by adding a second, closely-related test known as ethyl sulfate.&lt;/p&gt;

&lt;p&gt;This enhances the alcohol intake detection capacity of EtG but does not extend its window of detection beyond – at best – 5 days, often less. [Bean]&lt;/p&gt;

&lt;p&gt;Helander et al. have recently concluded that “&lt;em&gt;…EtS&lt;/em&gt; [ethyl sulfate]&lt;em&gt; testing should accompany, be used to verify, or in the future possibly replace EtG testing.&lt;/em&gt;”&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Prospects for Ethyl Glucuronide Testing in an Underwriting Context&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What cutoff has been proposed for EtG testing in underwriting? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;“…somewhere in the 0.5 mg/L range.” [private communication from an industry provider]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does this present any problems? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes, it would mean positives due to the aforementioned causes of false-positives and could also lead to distorted results based on elevated creatinine and marijuana use.&lt;/p&gt;

&lt;p&gt;The extent of these interferences has yet, as regards most of them, to be fully ascertained.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How might EtG be deployed if it were used in underwriting? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;It has been suggested that one might perform EtG based on elevated liver enzymes. Then, if EtG is positive, further reflex to CDT or possibly HAA. This is held to be a way of minimizing excessive spending on the more costly CDT and HAA tests. [private communication from an industry provider]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Could we screen with EtG? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;No, that makes no sense given its modest window of detection and the fact that all we can say of any person who tests positive is that they consumed some quantity of alcohol within that interval. Consuming alcohol, per se, means nothing in our context…unlike the above-mentioned clinical contexts.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Should we consider reflexing in the above-mentioned manner, based on an “elevated liver enzyme”? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Not if that enzyme is ALT, or AST when it is not more than two times higher than ALT, and in the absence of another probable cause.&lt;/p&gt;

&lt;p&gt;Unfortunately, when one examines the reasons for which insurers say they now order CDT and/or HAA reflexive testing, a number make little or no sense to this underwriter.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;If GGT is elevated and EtG is negative, what do we know? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Assuming the EtG is not a false-negative, all we know is that someone who may nevertheless be a heavy drinker (especially a binge drinker, with perhaps the greatest short-term excess mortality of any mode of overuse) has likely not consumed alcohol for a period of not longer than 5 days and quite possibly less.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does the use of EtG in the context of isolated elevated GGT raise any other issues regarding how we assess an elevated GGT reading? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes…and this is of particular concern because we have yet to recognize, as an industry, the overwhelming association between elevated GGT and the risk of CV disease. We have covered this in our CE course on GGT and it would be refreshing for those who set underwriting criteria to factor this important information into their guidelines for assessing GGT.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Do the causes of false-positives due to factors unrelated to beverage alcohol intake have implications for us in underwriting? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Absolutely.&lt;/p&gt;

&lt;p&gt;This would mean that many persons with GGT elevated due to non-alcohol-related reasons plus EtG elevated due to mouthwash, etc. would require “double-reflexing” (GGT to EtG to CDT).&lt;/p&gt;

&lt;p&gt;Furthermore (as we have reported many times), there is very modest overlap between GGT and CDT in terms of pinpointing heavy drinking. Thus, if GGT is elevated and ETG is also elevated, it is still more likely that CDT will yield more false-negatives than true-positives in this setting.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is there any other consideration which must be borne in mind if we consider using EtG in underwriting? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes.&lt;/p&gt;

&lt;p&gt;As Helander et al. have pointed out, EtG testing has already led to “adverse publicity” because it elevates from unintentional alcohol intake due to mouthwash use, hand sanitizers, etc.&lt;/p&gt;

&lt;p&gt;Because of existing concerns about this test in non-underwriting contexts, its deployment in underwriting could lead to challenges from some quarters in ways not associated with other prospective new testing alternatives (which likely represent a better use of our budget dollars).&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;In consideration of the foregoing, do you believe we should deploy EtG testing in underwriting at this time? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;No.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Then how do we deal with screening test results suspicious for alcohol abuse? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;By relying less on reflexive testing and more on (real) underwriting!&lt;/p&gt;

&lt;p&gt;This means seeing the elevated GGT (or whatever) in the CONTEXT of the whole case.&lt;/p&gt;

&lt;p&gt;Based on the findings in the 2007 Underwriting Requirements Survey, as well as audits we have done, we conclude that 50% or more of alcohol-related reflexive testing currently done is not only unnecessary per se…&lt;/p&gt;

&lt;p&gt;…but also culminates in underwriting decisions inferior to those that would have been made if we had devoted more time to assessing the whole risk in CONTEXT…and then making the best possible offer on that basis.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;References&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Bean. Personal Communication&lt;br /&gt;
Beck. &lt;em&gt;Alcohol and Alcoholism. &lt;/em&gt;42(2007):321&lt;br /&gt;
Borucki. &lt;em&gt;Alcoholism: Clinical and Experimental Research.&lt;/em&gt; 29(2005):781&lt;br /&gt;
Costantino. &lt;em&gt;Journal of Analytic Toxicology&lt;/em&gt;. 30(2006):659&lt;br /&gt;
Dahl.&lt;em&gt; Journal of Analytic Toxicology&lt;/em&gt;. 26(2002):201&lt;br /&gt;
Halter.&lt;em&gt; International Journal of Legal Medicine&lt;/em&gt;. 122(2008):123&lt;br /&gt;
Helander. &lt;em&gt;Clinical Chemistry&lt;/em&gt;. 53(2007):1855&lt;br /&gt;
Morini. &lt;em&gt;Clinica Chimica Acta.&lt;/em&gt; 376(2007):213&lt;br /&gt;
Skipper. &lt;em&gt;Alcohol and Alcoholism.&lt;/em&gt; 39(2004):445&lt;br /&gt;
Wojcik. &lt;em&gt;Alcohol and Alcoholism. &lt;/em&gt;42(2007):317&lt;br /&gt;
Wurst. &lt;em&gt;Alcoholism: Clinical and Experimental Research.&lt;/em&gt; 2992005):465&lt;br /&gt;
Wurst and Skipper. &lt;em&gt;Addiction. &lt;/em&gt;98, Supplement 2(2003):51&lt;br /&gt;
Wurst and Wiesbeck. &lt;em&gt;Alcoholism: Clinical and Experimental Research.&lt;/em&gt; 28(2004);1220&lt;/p&gt;
&lt;/div&gt;
          &lt;/div&gt;

    &lt;/div&gt;
  &lt;/div&gt;

</description>
  <pubDate>Tue, 01 Apr 2008 13:01:09 +0000</pubDate>
    <dc:creator>hankgeorge</dc:creator>
    <guid isPermaLink="false">25656 at https://rtaylor193.github.io/insureintell-1col</guid>
    </item>
<item>
  <title>Rx Compliance in the Elderly</title>
  <link>https://rtaylor193.github.io/insureintell-1col/node/25657</link>
  <description>  &lt;div data-history-node-id="25657" class="layout layout--onecol"&gt;
    &lt;div class="layout__region layout__region--content"&gt;
      
  &lt;div&gt;
    &lt;div&gt;Body&lt;/div&gt;
              &lt;div property="schema:text"&gt;&lt;p&gt;&lt;em&gt;Note to Readers:&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;This article supplements our March CE course on Rx Compliance in the general population. Because of the length of that course, we decided to publish this additional material for all registered web site members to see. &lt;/em&gt;&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Why is this subject so important? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Because of the heavy use of pharmaceuticals at ages 65 and over, a phenomenon sometimes described as “polypharmacy.”&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Do older-aged persons use more Rx? &lt;/strong&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;&lt;em&gt;“Although only about 13% of the US population is over age 65, this segment uses more than 30% of prescription and 35% of OTC&lt;/em&gt; [over-the-counter] &lt;em&gt;drugs.” &lt;/em&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;Mark H. Beers&lt;br /&gt;
&lt;em&gt;American Journal of Managed Care &lt;/em&gt;&lt;br /&gt;
6(2000):1313&lt;/p&gt;
&lt;/blockquote&gt;
&lt;/blockquote&gt;

&lt;p&gt;&lt;strong&gt;Do the words “compliance,” “adherence” and “persistence” all mean essentially the same thing in an Rx context? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes – although in some studies they are used to make distinctions that have little or no relevance to us in underwriting.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does patient age affect Rx compliance? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In one large study, compliance was best at ages 55-64, then dropped off progressively at 65-75 and 75+, to the point where it was worse than at ages 45-54. [Chapman]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What % of older age persons are noncompliant (defined as failing to take a drug at least 80% of the time, as indicated on the pill bottle)? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;52%. [Sherman]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Do prescription refill records overestimate compliance in older age people? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes – which means that if we have access to and make use of Rx refilling records, our estimate of actual noncompliance will be a conservative one. [MacLaughlin]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What % of geriatric hospitalizations for circulatory problems are thought to be due to noncompliance? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;50%. [Col]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What factors have been shown to affect compliance in the elderly?&lt;/strong&gt; [Bambauer, Col, Friedlander, Kulkarni, Ownby, Soumerai, Tsai]&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Living alone&lt;/li&gt;
	&lt;li&gt;Unmarried&lt;/li&gt;
	&lt;li&gt;The presence of depression&lt;/li&gt;
	&lt;li&gt;Bereavement&lt;/li&gt;
	&lt;li&gt;Relatively lower income&lt;/li&gt;
	&lt;li&gt;Education less than high school (12 years of formal education)&lt;/li&gt;
	&lt;li&gt;Low levels of health literacy (not understanding their ailments)&lt;/li&gt;
	&lt;li&gt;Lack of sufficient English reading ability&lt;/li&gt;
	&lt;li&gt;Self-rated health less than EXCELLENT or VERY GOOD&lt;/li&gt;
	&lt;li&gt;Comorbid illnesses (having 2 or more impairments vs. just 1)&lt;/li&gt;
	&lt;li&gt;Having 1 or more ADL impairments&lt;/li&gt;
	&lt;li&gt;Forgetfulness/benign memory impairment&lt;/li&gt;
	&lt;li&gt;Clinical cognitive disorder&lt;/li&gt;
	&lt;li&gt;More complex drug-taking regimen&lt;/li&gt;
	&lt;li&gt;Receiving prescriptions from more than one doctor&lt;/li&gt;
	&lt;li&gt;Lack of insurance/ability to pay&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;How common is cost-related noncompliance? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In a study of nearly 14,000 older persons with access to Medicare benefits, noncompliance due to inability to afford prescribed drugs was 13% overall and 29% if disabled, due to inability to afford prescribed drugs. [Soumerai]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Do older age patients tend to know the drugs they take better than younger persons? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;No – in a Brooklyn, NY study, at age 66 and over only 8.3% of subjects knew the names of all their drugs, as compared to 62% under age 50 and 17% at 51-65. [Makaryus] No doubt polypharmacy was a major reason for this sharp decline.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is geriatric polypharmacy rare? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Hardly…just look at a series of MD reports on applicants with multiple impairments and you will see what we mean!&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What role does polypharmacy play? &lt;/strong&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;&lt;em&gt;“Among the elderly, the use of multiple medications resulting in complicated drug regimens is an important barrier to medication adherence.” &lt;/em&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;Jeannie L. Lee, PharmD et al.&lt;br /&gt;
Walter Reed Hospital&lt;br /&gt;
&lt;em&gt;Journal of the American Medical Association &lt;/em&gt;&lt;br /&gt;
296(2006):2563&lt;/p&gt;
&lt;/blockquote&gt;
&lt;/blockquote&gt;

&lt;p&gt;&lt;strong&gt;What level of polypharmacy is strongly associated with a high degree of noncompliance? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In a Canadian study, taking 11 or more drugs within a period of one year. [Grant]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Do all studies support a significant degree of noncompliance in polypharmacy over age 65? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;No, in the above-mentioned Canadian study, compliance actually improved between 1 drug and 7 drugs being taken and only became adverse at higher levels.[Grant]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What works synergistically with the number of drugs being taken to cause noncompliance to increase? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;The complexity of the drug regimen, as in:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;How many pills needed&lt;/li&gt;
	&lt;li&gt;How many times taken each day&lt;/li&gt;
	&lt;li&gt;Use of a non-pill delivery system such as a patch or by self-injection&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;What is the association between geriatric polypharmacy and the risk of a serious adverse drug reaction (requiring hospitalization and/or potentially life-threatening)? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;It doubles when utilization increases from 1 to 4 drugs and then is 14-fold greater at a level of 7 drugs being taken at the same time. [Beers]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is there excess mortality in geriatric polypharmacy? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In one study among older community-dwelling subjects, patients taking 5 or more medications had twice the mortality as those taking less, independent of the risks associated with the reasons for which they were taken. [Mazzaglia]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is the risk of being hospitalized also greater in polypharmacy? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes – in the same study, patients taking 5 or more drugs were 2.2 times more likely to require hospitalization; again, independent of the reasons for which the drugs were taken.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Did this study show anything else of underwriting interest? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Absolutely…the fact that subjects who had been hospitalized within the past 6 months had 2.8-fold increased mortality as compared to those who had not!&lt;/p&gt;

&lt;p&gt;Being hospitalized within 6 months also increased the risk of future hospitalization 3.6 times expected.&lt;/p&gt;

&lt;p&gt;These findings suggest that we must pay close attention to recent hospitalizations in elderly applicants, independent of the reason…and more carefully review their histories (including inpatient test findings!) in cases involving recent hospital discharge for any reason.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does Rx compliance in the elderly decrease over time after discharge from inpatient care? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes, in a variety of drugs. [Sud]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is 1-year Rx compliance with common cardiac drugs at older ages? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In a cohort of Canadian patients who had experienced an MI – which should motivate them to take their medications! – the following % were noncompliant after 12 months: [Simpson]&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Aspirin 25%&lt;/li&gt;
	&lt;li&gt;Lipid drugs 16%&lt;/li&gt;
	&lt;li&gt;Beta-blockers 26%&lt;/li&gt;
	&lt;li&gt;ACE inhibitors 30%&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;How good is statin Rx compliance at older ages? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Benner et al. found that compliance by pill count was 79% after 3 months but trailed off to 56% thereafter.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does statin compliance affect mortality in older age post-MI patients? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Significantly…mortality being 25% higher after 3 months in those with poor compliance, as compared to patients deemed “fully compliant.” [Rasmussen]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How about compliance with BP drugs? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yet another Canadian study showed 75% compliance after 1 year, declining to only 45% after 48 months [Perreault] – and we might add that compliance is likely to be lower in the US because of greater patient out-of-pocket cost.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is compliance better in congestive heart failure? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Brown and Shannon found that compliance was reported to be 80% overall in various studies but that when they used refill data, only 10% of digitalis users filled enough prescriptions to be able to use the drug in the manner prescribed.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does this have implications for CHF patient outcomes? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes – in their study, Brown and Shannon found that a 2.6% decline in compliance resulted in a 6.1% increased incidence of hospitalization.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Have any specific factors been linked to geriatric noncompliance with heart failure Rx? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes – comorbid depression, which has been shown to lessen compliance in almost every Rx scenario! [Moser]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Are most geriatric T2 diabetics compliant with oral medications? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;A web-based survey found that 30% miss at least one dose per week. [Hahn]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How is compliance in osteoporosis? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In a word: lousy!&lt;/p&gt;

&lt;p&gt;Ettinger found that after 1 year of ostensible treatment only 36.9% who received daily bisphosphonates and 54.6% who received these drugs weekly remained on therapy.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What are the implications of all of the relatively high noncompliance rates cited here? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;They correlate directly with excess morbidity and mortality.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Are there specific implications for underwriting? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes…the fact that we tend to accept what is stated on applications.&lt;/p&gt;

&lt;p&gt;In other words, if an applicant says he/she is “taking simvastatin,” we simply assume it is true and may use this as a favorable factor in determining insurability.&lt;/p&gt;

&lt;p&gt;This is especially true where preferred risk coverage is offered, because being hypertensive or hyperlipidemic on treatment does not automatically disqualify the individual from getting preferred (sometimes super-preferred) premium rates in the great majority of companies.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How can we improve the quality of the information we get where underwriting noncompliance is concerned? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;To do so, we must accept that not inquiring specifically – as is the case with traditional applications in the absence of teleinterviews – is not going to generate much information about Rx-taking practices. This is not something applicants will volunteer unasked.&lt;/p&gt;

&lt;p&gt;To make effective use of this aspect of insurability, we MUST do teleinterviews and include questioning about Rx compliance on all relevant drilldowns.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How can we enhance disclosure of Rx-taking practices on teleinterview drilldowns? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;If we ask something straightforward (“do you take your medication as prescribed”), the odds of getting a YES – when the real answer is NO – are higher than if we ask, for example, thusly: “how many times per week do take your medication?” At least this has been our experience.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Can we rely on medical records for reliable information on Rx compliance? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;You probably think the answer is yes…but it isn’t.&lt;/p&gt;

&lt;p&gt;Where their Rx use practices are concerned, patients are simply less likely to tell their doctors the truth than they are strangers calling them to complete the insurance-buying process! They don’t want to disappoint their physician or get a lecture.&lt;/p&gt;

&lt;p&gt;Physicians are also notorious for not recording observations related to compliance (assuming that they even ask).&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Do Americans have a huge advantage where assessing Rx compliance is concerned? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;They really do…because they can get Rx profile reports – based directly on pharmacy records – for 70% or more of their applicants.&lt;/p&gt;

&lt;p&gt;We have found that the true value of Rx profiling is significantly underappreciated unless one understands the insurability implications of not refilling prescriptions (as we have tried to show here).&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Are there any other major underwriting considerations associated with compliance that we need to focus on? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes – one – and we get into detail about it and its ramifications in our CE course on compliance.&lt;/p&gt;

&lt;p&gt;We refer here to what is widely recognized as the “healthy adherer effect,” which is summed up by one team of physicians as follows:&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;&lt;em&gt;“…patients who take their medication as prescribed are more likely to engage in a broad spectrum of health-promoting behaviors that lower the risk of mortality.” &lt;/em&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;M. Alan Brookhart, et al.&lt;br /&gt;
Harvard&lt;br /&gt;
&lt;em&gt;American Journal of Epidemiology &lt;/em&gt;&lt;br /&gt;
166(2007):348&lt;/p&gt;
&lt;/blockquote&gt;
&lt;/blockquote&gt;

&lt;p&gt;&lt;strong&gt;Do you have some examples of health-related factors associated with Rx compliance? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes – but research into this domain is still in its relative infancy:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Temperate alcohol use (vs. heavy drinking or being an ex-drinker)&lt;/li&gt;
	&lt;li&gt;Not smoking cigarettes&lt;/li&gt;
	&lt;li&gt;Being compliant with MD advice for routine screening tests such as mammograms, fecal occult blood, etc.&lt;/li&gt;
	&lt;li&gt;Consuming healthier diets&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;And the list goes on and on…all of which suggests that we should be exploring the potential for including some of these “healthy adherer” markers in how we appraise risks!&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is this article an example of how your CE courses are formatted? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes, in terms of basic layout but with 3 important differences:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;CE courses are provided in both PDF and WORD documents. WORD documents, of course, are easily edited, allowing users to adjust the content to fit their own underwriting practices and viewpoints on specific issues.&lt;/li&gt;
	&lt;li&gt;CE courses include LEARNING POINTS at the end of each segment.&lt;/li&gt;
	&lt;li&gt;CE courses contain SELF EXAMINATIONS with true/false and multiple choice questions (linked back to the text, so that participants can validate the correct answer).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Can we get a sample CE course? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes!&lt;/p&gt;

&lt;p&gt;Just e-mail Esther at &lt;a href="mailto:esther@hankgeorge.com"&gt;esther@hankgeorge.com&lt;/a&gt; and ask her for a CE sample course.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Bibliography&lt;/strong&gt; &lt;/p&gt;

&lt;p&gt;Bambauer. &lt;em&gt;Archives of General Psychiatry&lt;/em&gt;. 64(2007):602&lt;br /&gt;
Benner.&lt;em&gt; Journal of the American Medical Association.&lt;/em&gt; 288(2002):455&lt;br /&gt;
Brown and Shannon. &lt;a href="http://www.AJConline.org" title="www.AJConline.org"&gt;www.AJConline.org&lt;/a&gt; January, 2008&lt;br /&gt;
Chapman. &lt;em&gt;Archives of Internal Medicine.&lt;/em&gt; 165(2005):1147&lt;br /&gt;
Col. &lt;em&gt;Archives of Internal Medicine.&lt;/em&gt; 150(1990):841&lt;br /&gt;
Ettinger. &lt;em&gt;Arthritis &amp; Rheumatism.&lt;/em&gt; 15,Supplement(2004):S513&lt;br /&gt;
Friedlander.&lt;em&gt; Journal of the American Geriatric Society.&lt;/em&gt; 55, 4, Supplement(2007)S60&lt;br /&gt;
Grant. &lt;em&gt;Archives of Internal Medicine. &lt;/em&gt;164(2004):2343&lt;br /&gt;
Hahn. &lt;em&gt;Diabetes&lt;/em&gt;. 55,Supplement 1(2006):A196&lt;br /&gt;
Kulkarni. &lt;em&gt;American Heart Journal. &lt;/em&gt;151(2006):185&lt;br /&gt;
MacLaughlin.&lt;em&gt; Drugs and Aging.&lt;/em&gt; 22(2005):231&lt;br /&gt;
Makaryus. &lt;em&gt;Mayo Clinic Proceedings.&lt;/em&gt; 80(2005):991&lt;br /&gt;
Mazzaglia. &lt;em&gt;Journal of the American Geriatric Society&lt;/em&gt;. 55(2007):1955&lt;br /&gt;
Moser. &lt;em&gt;Circulation.&lt;/em&gt; 114,Supplement 2(2006):II-518&lt;br /&gt;
Ownby. &lt;em&gt;Geriatrics&lt;/em&gt;. 61(2006):30&lt;br /&gt;
Perreault. &lt;em&gt;Annals of Pharmacotherapy.&lt;/em&gt; 39(2005):1401&lt;br /&gt;
Rasmussen. &lt;em&gt;Journal of the American Medical Association.&lt;/em&gt; 297(2007):177&lt;br /&gt;
Sherman. &lt;em&gt;Geriatrics. &lt;/em&gt;62(2007):5[editorial]&lt;br /&gt;
Simpson. &lt;em&gt;American Heart Journal.&lt;/em&gt; 145(2003):438&lt;br /&gt;
Soumerai. &lt;em&gt;Archives of Internal Medicine. &lt;/em&gt;166(2006):1829&lt;br /&gt;
Sud. &lt;em&gt;Annals of Pharmacotherapy.&lt;/em&gt; 39(2005):1792&lt;br /&gt;
Tsai.&lt;em&gt; Journal of Glaucoma. &lt;/em&gt;12(2003):393&lt;/p&gt;
&lt;/div&gt;
          &lt;/div&gt;

    &lt;/div&gt;
  &lt;/div&gt;

</description>
  <pubDate>Sat, 01 Mar 2008 05:00:00 +0000</pubDate>
    <dc:creator>hankgeorge</dc:creator>
    <guid isPermaLink="false">25657 at https://rtaylor193.github.io/insureintell-1col</guid>
    </item>
<item>
  <title>Underwriting Serum Ferritin</title>
  <link>https://rtaylor193.github.io/insureintell-1col/node/25658</link>
  <description>  &lt;div data-history-node-id="25658" class="layout layout--onecol"&gt;
    &lt;div class="layout__region layout__region--content"&gt;
      
  &lt;div&gt;
    &lt;div&gt;Body&lt;/div&gt;
              &lt;div property="schema:text"&gt;&lt;p&gt;&lt;strong&gt;Why is this subject important? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;“A high serum ferritin level may serve as a surrogate marker for poor health.” &lt;/em&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;Raymond Gambino, MD&lt;br /&gt;
&lt;em&gt;LAB REPORT &lt;/em&gt;&lt;br /&gt;
17(1995):91&lt;/p&gt;
&lt;/blockquote&gt;

&lt;p&gt;We can say the same for an abnormally low serum ferritin, especially in males over 50 and post-menopausal females, doubly so if they are known to have microcytic/Fe-deficiency anemia or GI symptoms.&lt;/p&gt;
&lt;!--break--&gt;&lt;!--break--&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is ferritin? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;An iron-binding protein.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is the “normal range” for ferritin? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;There is some variance between laboratories (as is true with so many tests). That said, the normal ranges cited by Wallach in his widely used lab handbook are:&lt;/p&gt;

&lt;table border="1" width="344"&gt;
	&lt;tbody&gt;
		&lt;tr&gt;
			&lt;td width="137"&gt;
			&lt;div align="center"&gt;&lt;strong&gt;Age Grouping&lt;/strong&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td width="191"&gt;
			&lt;div align="center"&gt;&lt;strong&gt;Normal Range ng/mL or mcg/L &lt;/strong&gt;(µmol/L)&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;6 mos-15 years&lt;/td&gt;
			&lt;td&gt;7-142 (16-320)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Adult male&lt;/td&gt;
			&lt;td&gt;20-300([45-675)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Adult female&lt;/td&gt;
			&lt;td&gt;15-120 (34-270)&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;Others set ranges between 13-60 (29-135) on the low end, and 123-651 (277-1465) on the high end.&lt;/p&gt;

&lt;p&gt;Bottom line?&lt;/p&gt;

&lt;p&gt;You must know the normal range of any ostensibly abnormal ferritin result reported in medical records before you can use it in risk assessment.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Why did you show ferritin values in nanograms per milliliter, micrograms per liter, and micro-moles per liter? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Because ng/mL is the measurement used in the USA and the two are measurements used elsewhere.&lt;/p&gt;

&lt;p&gt;Hereafter we will show ng/mL, but you can easily convert to µmol/L by multiplying the ng/mL reading x 0.445.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How does menopause affect ferritin? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In one study of bodily iron stores in healthy postmenopausal US females, 3% had very low readings (&lt; 12) and 10% had readings &gt; 200. [Liu]&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Would you expect the same pattern in premenopausal women? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;No…because of the prevalence of significant menstrual blood loss, we would expect, if anything, the reverse, with low readings much more common than high.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;When is ferritin testing done clinically? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;It is not, as you know, a routine part of blood profile testing.&lt;/p&gt;

&lt;p&gt;The main clinical uses of ferritin testing would be:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Determine presence and extent of Fe (iron) overload in known/suspected primary (hereditary) or secondary iron overload disorders.&lt;/li&gt;
	&lt;li&gt;Predict and monitor degree of iron deficiency.&lt;/li&gt;
	&lt;li&gt;Determine response to Fe therapy or compliance with treatment.&lt;/li&gt;
	&lt;li&gt;Differentiate Fe deficiency from other types of microcytic (low MCV) anemia.&lt;/li&gt;
	&lt;li&gt;Monitor iron status in patients with chronic kidney disease, hemochromatosis, etc.&lt;/li&gt;
	&lt;li&gt;As you can see, the range of uses predicts that we will often see ferritin reported in medical records.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is the first question to ask when you see ferritin reported? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Why it was done…NOT whether or not it is normal (that’s the second question).&lt;/p&gt;

&lt;p&gt;How common is elevated serum ferritin in the general North American population (without regard to the presence vs. absence of disease)?&lt;/p&gt;

&lt;p&gt;6% overall. [Adams]&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is transferrin saturation (TS)? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Another measure of iron overload, more sensitive but less specific than ferritin.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How common is ferritin elevation in persons with TS elevation, again in the absence of known disease? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;9% in males under 45 and 13% in females under 35, increasing to as much as 22% in males over 62 and 21% in females over 62. [Looker]&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is very high ferritin common overall among persons hospitalized, without regard to the reason? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes – 7% in one study [Lee, M. H.], which supports the opening observation by lab guru Raymond Gambino.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Why does ferritin increase in persons with a higher likelihood of disease?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Because it functions as an acute phase reactant…that is, a marker for inflammation.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does inflammation affect TS in the same way? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;No, it tends to lower TS, which is one reason why elevated ferritin in the presence of a normal or low TS reading is a clue to a cause other than iron overload. [Looker]&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does ferritin vary day-to-day in otherwise healthy people? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes, by as much as 15%, according to another lab guru named Ravel.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What factors interfere with ferritin reading validity? &lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Recent transfusion or, possibly, donating blood.&lt;/li&gt;
	&lt;li&gt;Recent ingestion of a meal with high iron content.&lt;/li&gt;
	&lt;li&gt;Hemolytic disease may cause an artificially high reading.&lt;/li&gt;
	&lt;li&gt;Menstruation may cause a lower-than-normal reading.&lt;/li&gt;
	&lt;li&gt;Pregnancy, also lowering the reading.&lt;/li&gt;
	&lt;li&gt;Use of iron supplementation therapy.&lt;/li&gt;
	&lt;li&gt;Minimal elevation possible when taking oral contraceptives.&lt;/li&gt;
	&lt;li&gt;Low ferritin with daily aspirin use, even at one-a-day level intake. [Haidari]&lt;/li&gt;
	&lt;li&gt;No other commonly taken drugs are known to be associated with elevated readings according to the American Association for Clinical Chemistry’s reference book on Rx effects on lab tests.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Which lab tests are associated with elevated or below-normal ferritin? &lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;GGT – elevated ferritin is associated with elevated GGT, especially when heavy drinking is suspected and even in the absence of any known liver disease. [Kristenson]&lt;/li&gt;
	&lt;li&gt;ALT and AST – but likely only in the presence of known or occult liver damage or clinically-silent hemochromatosis. [AACC reference book]&lt;/li&gt;
	&lt;li&gt;Four pituitary hormones can exert a lowering effect: growth, follicle-stimulating, luteinizing and gonadotrophic – for what it is worth. [AACC reference book]&lt;/li&gt;
	&lt;li&gt;A few studies have shown higher levels in persons with elevated cholesterol or triglycerides. [AACC reference book]&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does temperate alcohol intake affect ferritin? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In one study “down under,” they found this in otherwise healthy people [Rossi]:&lt;/p&gt;

&lt;table border="1" width="384"&gt;
	&lt;tbody&gt;
		&lt;tr&gt;
			&lt;td rowspan="2" width="147"&gt;
			&lt;div align="center"&gt;&lt;strong&gt;Alcohol Intake/Day (grams/day)&lt;/strong&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="2"&gt;
			&lt;div align="center"&gt;&lt;strong&gt;Mean Ferritin Reading (ng/mL/mcg/L) &lt;/strong&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td width="106"&gt;
			&lt;div align="center"&gt;&lt;strong&gt;Males&lt;/strong&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td width="109"&gt;
			&lt;div align="center"&gt;&lt;strong&gt;Females &lt;/strong&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;1-10 (≤ 1 drink)&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;71&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;26&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;11-50 (1-4 drinks)&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;85&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;32&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;&gt;50 (4+ drinks)&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;104&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div align="center"&gt;72&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;Liu found similar results in postmenopausal females…ferritin increased but within the normal range at levels of 2-3/drinks per day (which is the upper level of “social drinking” stipulated for in women &lt; 65 years old by most experts).&lt;/p&gt;

&lt;p&gt;In other words, yes, temperate drinking (even as defined in my home state!) does increase ferritin, but not to any significant extent as far as we are concerned (that is, with the caveat that they did not segregate readings in persons consuming much higher levels!).&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Hyperferritinemia (Elevated Serum Ferritin)&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is alcohol liver disease associated with high ferritin? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Absolutely!&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does heavy intake of red meat increase ferritin levels? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Absolutely…but it would take a pretty devout carnivore to reach levels suggestive of undiagnosed disease! [Rossi]&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What other factors may significantly raise ferritin? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;One US study showed a higher incidence of elevations in obese persons and cigarette smokers…but the evidence for this does not appear sufficient in well persons to justify much concern in our view. [Kato]&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Do highly trained athletes have higher ferritin levels than other people of the same age? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes, it would seem they do.&lt;/p&gt;

&lt;p&gt;Lippi found that professional competition cyclists had mean levels of 332 ng/mL as compared to 127 ng/mL in amateur cyclists, and concluded that “professional endurance athletes have serum ferritin concentrations that are 2-fold to 3-fold higher than those matched sedentary individuals and amateur athletes.”&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Do we have any clue as to why this is true? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes…Zotter showed that professional road cyclists use “excessive iron supplementation” – which is one form of blood doping designed to confer competitive advantage!&lt;/p&gt;

&lt;p&gt;Maybe they should start monitoring ferritin in professional athletes?&lt;/p&gt;

&lt;p&gt;Just kidding…&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What are the main pathological factors associated with elevated serum ferritin in the general population? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Zelber-Sagi found that both nonalcoholic fatty liver disease (NAFLD) and hyperinsulinemia (a prediabetic condition) were associated with high readings in a large unselected sample of the general population (in a country, we might add, where hereditary hemochromatosis is not very common!).&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does the presence of elevated ferritin in NAFLD correlate with an increased risk of NASH – that is, nonalcoholic steatohepatitis, the most significant type of NAFLD? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes…and also with an increased risk of advanced fibrosis in patients with NASH. [Trombini, Zelber-Sagi]&lt;/p&gt;

&lt;p&gt;Thus, elevated ferritin would be an adverse finding in NASH or un-biopsied NAFLD (which could be NASH), from an underwriting perspective.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is the same true in chronic hepatitis C? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Iron overload is significantly more common in chronic HCV than in the general population and elevated ferritin levels are found in 20-35% of patients. That said, recent studies now question at least five earlier ones that linked high ferritin to fibrosis.&lt;/p&gt;

&lt;p&gt;Last year, Guyader and her French colleagues found that ferritin was not fibrogenic (associated with inducing fibrosis) but that is was a valid surrogate marker for greater disease severity overall.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is high ferritin associated with known hyperglycemia? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes.&lt;/p&gt;

&lt;p&gt;Fumeron et al. studied 1,277 patients sorted by the presence (vs. absence) of hyperglycemia. They found that impaired fasting glucose (IFG) is associated with significantly increased readings, as compared to normoglycemic subjects.&lt;/p&gt;

&lt;p&gt;However, this does not mean that most IFG cases will have elevated readings; rather, it only means that the average readings are greater when fasting glucose is above normal but not high enough to be considered IFG.&lt;/p&gt;

&lt;p&gt;This is also wholly consistent with the earlier observation regarding the link between hyperinsulinemia and higher ferritin levels.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is the same true for diabetics? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Likely if they are obese Type 2 diabetics who have NAFLD (a very common scenario, one might add).&lt;/p&gt;

&lt;p&gt;Also in those few cases where (typically sudden onset, symptomatic) diabetes at age 45 or over is deemed to be due to hemochromatosis – with the iron overload accompanying hemochromatosis being the likely cause.&lt;/p&gt;

&lt;p&gt;Canturk and associates found that poor control in DM was particularly likely to correlate with elevated ferritin.&lt;/p&gt;

&lt;p&gt;Hughes reported that mean serum ferritin was also much higher in Chinese, Malay, Indian-Asian and Korean diabetics than in nondiabetics of the same ethnic origins.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is the best clue to NAFLD in obese diabetics? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Elevated ALT, with elevated AST in some cases if the ALT-to-AST ratio is ≤1, and there is no evidence of any other prevalent cause of ALT elevation such as chronic hepatitis C (also more common in diabetics, to muddy the waters!), chronic hepatitis B, etc.&lt;/p&gt;

&lt;p&gt;Does ferritin tend to be higher in the metabolic syndrome than in those free of this prevalent and insidious disorder?&lt;/p&gt;

&lt;p&gt;For sure…but remember that chronic hyperglycemia and NAFLD are also quite prevalent in this syndrome.&lt;/p&gt;

&lt;p&gt;In one study, the strongest link between elevated ferritin and metabolic syndrome was in those with hypertriglyceridemia (one of 5 criteria for the syndrome). [Vari]&lt;/p&gt;

&lt;p&gt;Trombini found that the incidence of hyperferritinemia increased as the number of metabolic syndrome criteria increased in any given patient.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is ferritin associated with cardiovascular disease? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;“Strong epidemiological evidence is available that iron is an important factor in the process of atherosclerosis.”&lt;/em&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;B. de Valk, MD and J. J. Marx, MD&lt;br /&gt;
&lt;em&gt;Archives of Internal Medicine &lt;/em&gt;&lt;br /&gt;
159(1999):1542&lt;/p&gt;
&lt;/blockquote&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is high ferritin associated with CAD? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes [You] and mostly at ages 50 and under as opposed to 60+. [Aronow, Haidari]&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Has anyone shown that elevated ferritin is linked to a greater degree of ischemia-related heart impairment? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Say et al. found that hypercholesterolemic patients showed a significant correlation between magnitude of serum ferritin and probability of impaired perfusion, wall motion abnormalities and irreversible defects on imaging and angiographic studies.&lt;/p&gt;

&lt;p&gt;Haidari in Iran found that males with angiographically-proven CAD had higher average ferritin readings than men who did not have disease…but the mean levels were well within the normal range for ferritin. Women, on the other hand, showed no evidence of an impact of ferritin in this context.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is high ferritin linked to an increased risk of MI? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Two studies showed a definite, if modest, link between ferritin and MI. This was more pronounced if there were other CAD-risk comorbidities present. [Klipstein-Grobusch, Tuomainen]&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is ferritin linked to excess CV mortality? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Sempos reviewed 16 studies and found that 88% of them did not show a significantly increased risk.&lt;/p&gt;

&lt;p&gt;On the other hand, van der A did establish that the highest tertile (top 3rd) of ferritin readings correlated with a 2-fold increased risk of stroke.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is the bottom line where ferritin and CV disease is concerned? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;While ferritin likely plays a role in the pathogenesis of atherosclerotic disease, it does not appear to be enough of a risk factor for us to consider in CV risk triage.&lt;/p&gt;

&lt;p&gt;That said, we would argue that more than moderately-elevated ferritin – especially when the cause has not been found and addressed – is definitely incompatible with preferred risk!&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is elevated ferritin linked to cancer? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In the celebrated Framingham Offspring Cohort, elevated serum iron – which undoubtedly will be associated with elevated ferritin as well in many cases – was clearly a risk factor for cancer, doubly so when HDL-C was &lt; 41. [Mainous]&lt;/p&gt;

&lt;p&gt;Neoplastic disease is commonly cited in lab manuals as one of the chief causes of hyperferritinemia.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Should we be particularly concerned when the ferritin is mega-elevated (as in &gt; 1000 ng/mL or &gt; 2250 µmol/L)? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;“Our findings suggest that serum ferritin extreme elevations&lt;/em&gt; [they used &gt; 1000]&lt;em&gt;, taken by themselves, are a non-specific indicator of significant disease…” &lt;/em&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;Mark H. Lee, MD, et al.&lt;br /&gt;
&lt;em&gt;The American Journal of Medicine &lt;/em&gt;&lt;br /&gt;
98(1995):566&lt;/p&gt;
&lt;/blockquote&gt;

&lt;p&gt;In other words, YES…it would not be incumbent upon us to offer insurance coverage in this context until a satisfactory workup was done to determine the cause of such a major elevation…&lt;/p&gt;

&lt;p&gt;…and if no cause were established and dealt with (which is not an uncommon outcome), we would still be steadfast in postponing consideration because some life-threatening diseases may be below the threshold of discovery early on.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What other factors would make us doubly reluctant to consider mega-elevations? &lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Age 65+&lt;/li&gt;
	&lt;li&gt;Recent weight loss ≥ 10% of pre-loss weight, especially if not credibly explained (as nicely documented by Hearnshaw)&lt;/li&gt;
	&lt;li&gt;Heavy, longtime cigarette smoking (as in pack years, not merely current use!)&lt;/li&gt;
	&lt;li&gt;Very low or falling cholesterol (in the absence of hypolipidemic Rx)&lt;/li&gt;
	&lt;li&gt;Low serum albumin&lt;/li&gt;
	&lt;li&gt;Elevated GGT&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What are the main causes of such mega-elevations?&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Neoplastic disease&lt;/li&gt;
	&lt;li&gt;Alcoholic liver disease; other chronic and advanced liver pathologies&lt;/li&gt;
	&lt;li&gt;Hematological diseases&lt;/li&gt;
	&lt;li&gt;Chronic inflammatory diseases which are clinically active (symptomatic)&lt;/li&gt;
	&lt;li&gt;Autoimmune diseases&lt;/li&gt;
	&lt;li&gt;Advanced renal disease&lt;/li&gt;
	&lt;li&gt;Symptomatic disease associated with HIV-1 infection&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Hypoferritinemia (Ferritin Readings Below Normal)&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What are the main causes of low serum ferritin? &lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;#1 is Fe deficiency anemia&lt;/li&gt;
	&lt;li&gt;Chronic blood loss, usually with anemia present&lt;/li&gt;
	&lt;li&gt;Disturbed iron absorption, which occurs in Crohn disease, more significant cases of celiac disease and other acute/chronic enteropathies (small bowel disorders)&lt;/li&gt;
	&lt;li&gt;Pregnancy&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is considered to be a low ferritin in someone with depleted iron stores due to known or suspected Fe deficiency? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt; 22 ng/mL. [Joosten]&lt;/p&gt;

&lt;p&gt;When the reading gets down to &lt; 12 ng/mL most experts concur that this is sufficient to make a diagnosis of iron deficiency.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Can asymptomatic hypoferritinemia be associated with serious disease? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes.&lt;/p&gt;

&lt;p&gt;In one important study, 5 of 64 asymptomatic older age patients with ferritin &lt; 50 ng/mL who had diagnostic colonoscopy were found to have occult colon cancer and 2 more in the same cohort had large premalignant adenomatous colon polyps. [John Lee]&lt;/p&gt;

&lt;p&gt;Among those with low ferritin who had upper GI endoscopy (132 patients) – whether symptomatic or not for undiagnosed illness – there were 2 cancers, 15 cases of advanced esophagitis and 31 patients with ulcers or erosions in either the stomach or the duodenum.&lt;/p&gt;

&lt;p&gt;Joosten performed upper and lower GI studies on 151 older-age individuals with low ferritin (in this case, &lt; 22 ng/mL or &lt; 50 µmol/L) and found 18 colon cancers, 5 of which were not associated with overt anemia (low hemoglobin).&lt;/p&gt;

&lt;p&gt;Lipato reported a 9.2% incidence of colon cancer in 414 subjects, mostly male and mean age 70, whose ferritin was &lt; 50 ng/mL.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is the correlation between low ferritin and hemoglobin levels? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;J.G. Lee reported that patients with very low (≤ 20 ng/mL) ferritin had a mean Hb (hemoglobin) of 11.1 g/dL, while those between 21 and 50 had an average Hb reading of 12.7.&lt;/p&gt;

&lt;p&gt;In other words, mild – rather than moderate-to-severe anemia – is the rule.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Did these patients also have low MCV readings?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Those with very low ferritin did; less so with readings in the 21-50 range…which means that ferritin is often an earlier indicator of risk than the presence of microcytosis.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is the colon cancer risk increased if ferritin is &gt; 100 ng/mL? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;No…but the authors who reported this also maintained that older patients with readings &lt; 100 “may benefit” from colonscopy. [Sawhney]&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is the bottom line on low ferritin? &lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;In Crohn disease or celiac disease, it portends a less favorable risk status.&lt;/li&gt;
	&lt;li&gt;In younger persons (premenopausal females; males under ago 50) it probably doesn’t confer much added risk; that is, unless there are uninvestigated symptoms or other risk factors (polyp-forming syndromes, for example).&lt;/li&gt;
	&lt;li&gt;At older ages, and progressively so at 65 and over, applicants with very low readings are – in our opinion – uninsurable, and we would maintain a high index of suspicion even between 21-50 ng/mL or 47-113 µmol/L depending on other case context factors.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Should we use ferritin as a screening test? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Overall…never.&lt;/p&gt;

&lt;p&gt;That said, one could fashion an argument for doing so at ages 65 and over based on all of the foregoing. Indeed, it would not surprise this underwriter if the protective value of screening with serum ferritin was higher than many of the things we do now at ages 65+.&lt;/p&gt;

&lt;p&gt;Moreover, as it is not a tumor marker, we wouldn’t have the problems that make tests like CEA and its kindred the potential nightmares for insurers that abundant experience has shown them to be.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Note to Readers &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;This paper on underwriting ferritin tests contains material originally intended to be included in our CE course on HEMOCHROMATOSIS…but that course turned out to be long enough, so we saved it for this project. &lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;The format of this course is similar to our CE and IE courses, giving you a good idea of what CE, in particular, is like. We hope you find it appealing in format, style and nature of content! &lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;&lt;strong&gt;Talk to us! Did you find this article helpful? How could it be improved? &lt;/strong&gt;&lt;/em&gt;&lt;br /&gt;
 &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Bibilography&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Adams. &lt;em&gt;The New England Journal of Medicine.&lt;/em&gt; 352(2005):1769&lt;br /&gt;
Aronow. &lt;em&gt;American Journal of Cardiology&lt;/em&gt;. 72(1993):347&lt;br /&gt;
Canturk. &lt;em&gt;Endocrinology Research.&lt;/em&gt; 29(2003):299&lt;br /&gt;
Fumeron. &lt;em&gt;Diabetes Care&lt;/em&gt;. 29(2006):2090&lt;br /&gt;
Gleeson. &lt;em&gt;American Journal of Gastroenterology. &lt;/em&gt;101(2006):304&lt;br /&gt;
Guyader. &lt;em&gt;Journal of Hepatology.&lt;/em&gt; 46(2007):587&lt;br /&gt;
Haidari. &lt;em&gt;Clinical Chemistry.&lt;/em&gt; 47(2001):1666&lt;br /&gt;
Hearnshaw. &lt;em&gt;World Journal of Gastroenterology. &lt;/em&gt;12(2006):5866&lt;br /&gt;
Hughes. &lt;em&gt;Arteriosclerosis.&lt;/em&gt; 136(1998):25&lt;br /&gt;
Joosten. &lt;em&gt;The American Journal of Medicine. &lt;/em&gt;107(1999):24&lt;br /&gt;
Kato.&lt;em&gt; International Journal of Vitamin and Nutrient Research. &lt;/em&gt;70(2000):119&lt;br /&gt;
Klipstein-Grobusch. &lt;em&gt;American Journal of Clinic Nutrition.&lt;/em&gt; 69(1999):1231&lt;br /&gt;
Kristenson.&lt;em&gt; Drug and Alcohol Dependence. &lt;/em&gt;8(1981):43&lt;br /&gt;
Lee, J. G. &lt;em&gt;American Journal of Gastroenterology. &lt;/em&gt;93(1998):772&lt;br /&gt;
Lee, M. H. &lt;em&gt;The American Journal of Medicine.&lt;/em&gt; 98(1995):566&lt;br /&gt;
Lipato. &lt;em&gt;American Journal of Gastroenterology.&lt;/em&gt; 99, Supplement (2004):S334&lt;br /&gt;
Lippi. &lt;em&gt;Clinical Journal of Sports Medicine.&lt;/em&gt; 15(2005):356&lt;br /&gt;
Liu. &lt;em&gt;American Journal of Clinical Nutrition.&lt;/em&gt; 78(2003):1160&lt;br /&gt;
Looker. &lt;em&gt;Annals of Internal Medicine.&lt;/em&gt; 129(1998):940&lt;br /&gt;
Mainous. &lt;em&gt;American Journal of Epidemiology.&lt;/em&gt; 161(2005):1115&lt;br /&gt;
Rossi. &lt;em&gt;Clinical Chemistry&lt;/em&gt;. 47(2001):202&lt;br /&gt;
Sawhney.&lt;em&gt; American Journal of Gastroenterology.&lt;/em&gt; 102(2007):82&lt;br /&gt;
Sempos. &lt;em&gt;Annals of Epidemiology.&lt;/em&gt; 10(2000):441&lt;br /&gt;
Trombini. &lt;em&gt;Journal of Hepatology.&lt;/em&gt;46(2007):549[editorial]&lt;br /&gt;
Tuomainen. &lt;em&gt;Circulation.&lt;/em&gt; 97(1998):1461&lt;br /&gt;
van der A. &lt;em&gt;Stroke. &lt;/em&gt;36(2005):1637&lt;br /&gt;
Vari. &lt;em&gt;Diabetes Care.&lt;/em&gt; 30(2007):1795&lt;br /&gt;
You. &lt;em&gt;Clinica Chimica Acta.&lt;/em&gt; 357(2005):1&lt;br /&gt;
Zelber-Sagi. &lt;em&gt;Journal of Hepatology.&lt;/em&gt; 46(2007):700&lt;br /&gt;
Zotter. &lt;em&gt;British Journal of Sports Medicine&lt;/em&gt;. 38(2004):704&lt;/p&gt;
&lt;/div&gt;
          &lt;/div&gt;

    &lt;/div&gt;
  &lt;/div&gt;

</description>
  <pubDate>Fri, 01 Feb 2008 13:01:09 +0000</pubDate>
    <dc:creator>hankgeorge</dc:creator>
    <guid isPermaLink="false">25658 at https://rtaylor193.github.io/insureintell-1col</guid>
    </item>

  </channel>
</rss>
